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Aim: The aim of the thesis is to introduce nitric oxide (NO) and its role in physiology 
and pathophysiolgy of central nervous system (CNS), with the intention of epileptiform 
activity in the nervous tissue. Our research was realized on rat hippocampal slices in 
vitro and it compares the experimental biochemical models (low-Mg2+, high-K+, 
Carbachol, Bicuculline and 4-Aminopyridine model). These changes in the environment 
of slice should evoke the epileptiform activity in the nervous tissue of the rat. The final 
aim of the thesis is to create an experimental model of epileptiform activity in vitro in 
our setup for imaging techniques and NO detection. 
 
Methods: Experiments were performed in rat hippocampal slices in vitro. Rats were 
deeply anaesthetized with ether and decapitated. Brain was rapidly removed from the 
scull, cut in oxygenated (95%) and cooled (0, 5 °C) artificial cerebrospinal fluid (ACSF) 
using vibratome in coronal slices of 400µm of thickness. They were submerged into 
recording chamber where ACSF in adequate concentration was perfused (5 ml/min and 
temperature ± 33 °C) using a peristaltic pump. Data recordings were made in the 
submerged type chamber. Synaptic activation of the tissue was made with bipolar 
stimulating electrode placed in hillus of the dentate gyrus of hippocampus (Mossy 
fibers). Detection electrode was placed in pyramidal layer of CA1 region. Single shock 
stimulation with supramaximal stimulus was applied and then other stimuli in 
determined values according to stimulation protocol. Experimental models were 
performed by changing the concentration of ions in the ACSF (low-Mg2+ and high-K+ 
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model) or by addition of chemical into this solution (Carbachol, Bicuculline and 4-AP 
model). 
 
Results: We evaluated eight hippocampal slices with following results. We haven’t 
been able to elicit tonic clonic seizures in our setup. The only model whose activity 
resembled to seizure activity was the high-K+ model (10mM). With low-Mg2+ (zero 
Mg2+), high-K+ (10mM), Bicuculline (13μM and 33μM) in combination with high-K+ 
(7mM KCl), 4-Aminopyridine (250μM), except for Carbachol treated slices, we were 
able to elicit epileptic discharges.  
 
Key words: nitric oxide (NO), epilepsy, hippocampus, low-Mg2+, high-K+, Carbachol, 
Bicuculline, 4-AP. 
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Cíl práce: Cílem této práce je představit oxid dusnatý (NO) a jeho roli ve fyziologii a 
patofyziologii centrálního nervového systému (CNS) se zaměřením na epileptickou 
aktivitu nervové tkáně. Náš výzkum, který byl proveden in vitro na potkaních 
hipokampálních řezech, porovnává experimentální biochemické modely (nízká 
koncentrace hořčíku Mg2+, vysoká koncentrace draslíku K+, Carbachol, Bicuculline a 4-
aminopyridine model). Takto změněné podmínky prostředí řezu by měly vyvolávat  
epileptickou aktivitu v nervové tkáni potkana. Konečným cílem práce je vytvoření 
optimálního experimentálního modelu epileptické aktivity in vitro, který je 
předpokladem pro další experimenty především pro optické zobrazovací techniky, 
jejichž pomocí jsme schopni detekovat NO. 
 
Metody: Měření bylo provedeno na řezech hippocampu laboratorních potkanů in vitro. 
Potkani byli dekapitováni v hluboké anestesii éterem. Mozek byl rychle exstirpován 
z lebky a nařezán v okysličeném (95%) a chlazeném (0,5 °C) uměle vytvořeném 
mozkomíšním moku s použitím vibratomu na frontální řezy o šířce 400 µm a uchovány 
po dobu nejméně 2h v ustalovací komůrce. Řezy byly poté přemístěny do nahrávací 
komůrky, kde byly zcela ponořeny do proudícího umělého mozkomíšního moku ( 5 
ml/min a při teplotě ± 33 °C ) a za použití peristaltického čerpadla. Stimulaci jsme 
prováděli bipolární stimulační elektrodou umístěné do oblasti hilus gyrus dentatus 
hippocampi. Detekční elektroda byla umístěna do pyramidové vrstvy v oblasti CA1. 
Experimentální modely byly vytvořeny změnou koncentrace iontů v uměle vytvořeném 
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mozkomíšním moku (u modelu s nízkou koncentrací hořčíku a vysokou koncentrací 
draslíku) nebo aplikací farmaka do tohoto roztoku (u modelu s použitím Carbacholu, 
Bicucullinu a 4-AP) .          
 
Výsledky: Hodnotili jsme osm hippocampálních řezů s těmito výsledky. Nepodařilo se 
nám vyvolat tonicko-klonické záchvaty epileptické aktivity na žádném z řezů a u 
žádného experimentálního modelu. Jediný model, který se svým průběhem přiblížil 
epileptické aktivitě byl model s vysokou koncentrací draslíku (10mM). Kromě modelu 
s použitím Carbacholu, jsme úspěšně vyvolali epileptické výboje u nízké koncentrace 
Mg2+, vysoké koncentrace K+ (10mM), Bicucullinu (13μM and 33μM) v kombinaci 
s vysokou koncentrací (7mM KCl) a 4-AP (250μM). 
 
Klíčová slova: oxid dusnatý (NO), epilepsie, hippocampus, nízká koncentrace Mg2+, 
vysoká koncentrace K+, Carbachol, Bicuculline, 4-AP.    
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1.  INTRODUCTION 
 
 
 Central nervous system is a leader, supervisor and coordinator of all processes in 
the human body. Thanks to CNS we are able to move, behave and live in the society 
with other people, all these complex functions are enabled by virtue of many 
biochemical processes that occur in molecular level. Neuron, electrically excitable 
neuronal cell is responsible for the transmission of the signal and neuronal 
communication in general. With increasing knowledge about processes in CNS and 
better equipment for the detection even in the cellular level we are discovering many 
new substances that can influence neuronal activity and help us to deal with different 
pathological states of the CNS. One of these discoveries is NO detection and 
determination its role in neuronal tissue. Having this gas as a signaling molecule, 
radically changed the whole concept of neural communication and posed many new 
questions that need to be elucidated.  
 Detection of this molecule poses some difficulties because of its gaseous 
characteristics. On the other hand, these characteristics bring some advantages because 
this small, uncharged and fat-soluble molecule can diffuse widely and readily enters the 
cells. 
 Control of the synthesis of NO is the key to regulating its activity and functional 
results. There are three known isoforms of NO synthases (NOS) and each of them has 
its specific function in human body; neuronal nNOS, endothelial eNOS and inducible 
iNOS. 
 NO seems to be mostly kept in mind as a smooth muscle relaxant with 
vasodilatation effect so that attached as a support in heart and cerebral stroke or penile 
erection where increasing a blood supply. But it is necessary to involve it into the 
functional context and realize that it has been related such an important processes like 
respiratory chain and Krebs cycle, running in mitochondria and processing the oxygen 
and generating the energy, essential for all organisms (Beltrán et al., 2000). Centrally 
released NO has been proposed in functions of CNS such a brain development, visual 
processing, discriminative learning, food and drink behaviour and many and many 
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others; but also in peripheral functions such a regulation of blood pressure, heart rate, 
gastric acid secretion, etc. It has been implicated in perception of pain when synthesis of 
NO enhances spinal facilitation of the afferent input whereas inhibition of NO can have 
antinociceptive effects. There is an evidence of overproduction of NO in cerebral 
ischemia caused by activation of nNOS and involved in neuronal damage but NO 
produced by eNOS in the same case play a protective role by maintaining regional 
cerebral blood flow. It is also related in numerous disorders of CNS and in the etiology 
of neurological conditions, including autoimmune and chronic neurodegenerative 
diseases. (Esplugues, 2002) 
  In the present studies, there is a tendency to investigate the role of NMDA/NOS 
system in epileptiform activity (Schuchmann, 2002). NMDA receptor is a specific type 
of ionotropic glutamate receptor. These receptors when tonically activated can trigger 
an excessive increase in intracellular calcium; nerve cells start to induce abnormal 
excessive activity and intracellular calcium accumulation or even get damaged, so 
called excitotoxicity. The activity of NO is dependent on the increased levels of 
intracellular Ca2+ and binding to calmodulin and that the connection between NMDA 
receptors and NO production. 
NO has been proposed as the retrograde messenger which co-ordinates the 
enhancement of both pre- and post-synaptic mechanism involved in two forms of 
synaptic plasticity; namely long-term potentiation (LTP) and long-term depression 
(LTD) (Esplugues, 2002). NO, respectively NOS, as a proposed mediator of LTP, 
influences the enzymatic activity in mitochondria and the whole process of LTP where 
the connection between neuronal cells can get improved in their strength relates to 
NMDA receptors. When these receptors are stimulated simultaneously with the 
sufficient strength, intersynaptic transport modulates in increasing postsynaptic cell’s 
sensitivity and finally leads into the enhancement of existing receptors’ activity or even 
their amount. Then called the process of modulation, it underlies learning and memory 
as a major cellular mechanism; and when lasting longer, these changes in brain are 
thought to participate in construction of neuronal circuits during development and to 
relate to long-term formation of engrams. 
This process of learning, modulation and synaptic plasticity reminds a work of 
physiotherapist who teaches the patient how to recover lost function of the movement or 
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reeducates him the new one. This work is not fixed on the muscle but the supervision, 
central nervous system. According to this statement there is no doubt that this treatment 
should be mostly aimed on the function of organ, not on its structure, in accordance 
with idiom of St. Hilaire “The function forms organ” and by the name of principles of 
neuroplasticity. 
  We know that NO is involved in many aspects of CNS function but we are still 
far away from the pharmacological breakthrough which could have a clinical impact in 
CNS released diseases. The experimental knowledge continues to grow and recent 
important findings, including the role of NO in CNS, help to raise a prospect of future 
therapeutic leads, thus achieving the pharmacological goal of linking physiological 
knowledge with drug development. This physiological knowledge will help not only to 
doctors in pharmacological treatment but also to other occupations in medicine, such as 
physiotherapist, ergotherapist, medical technicians etc. Because these clinicians do not 
work only in routine practice of hospitals and similar institutions, but they cooperate in 
researches of many clinical branches. Moreover, they are expected, as the graduated of 
Master’s degree, to know all of the contexts of disorders which they treat and to use 
these in their treatment. They are also expected to be a part of educational system in 
clinical medicine and to hand on their experiences and skills to other students. All of 
that makes them an essential part of multidisciplinary team. 
 There are many investigations in progress in the laboratory conditions of Czech 
Academy of Science to determine the physiological and pathophysiological aspects of 
disorders of CNS such a cerebral stroke or epilepsy, on animal models both in vitro and 
in vivo. We are focused on the detection of NO in epileptiform activity. For this purpose 
we have to create a functional and optimal model of these seizures, applicable in our 
setup, first of all in vitro, on rat hippocampal slices which are passed for the most 
suitable tissue for this research because of its unidirectional connectivity, similarity to 
the human structure and very well known morphology. 
 Success in these models in vitro anticipates following investigations in vivo and 
imaging techniques; for detection and determination the role of nitric oxide, possibly 
miraculous signaling molecule, in CNS.  
 
 13
2.  THEORETICAL BACKROUND 
 
 
2.1  ANATOMY 
 
 
2.1.1  NEURON AND GLIA 
 
 Neuron is a nerve cell. It is an electrically excitable cell that processes and 
transmits information by electrochemical signaling. (Levitan & Kaczmarek, 1997) 
 
 
Figure 2.1: Neuron and its structure (Image 1) 
 
 
 Glia is non-neuronal cell that maintain homeostasis, forms myelin, and provides 
support and protection for the brain's neurons. (Azevedo et al., 2009) 
 Some glial cells function primarily as the physical support for neurons. Others 
regulate the internal environment of the brain, especially the fluid surrounding neurons 
and their synapses, and nourish neurons. During early embryogenesis, glial cells direct 
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the migration of neurons and produce molecules that modify the growth of axons and 
dendrites. Recent research indicates that glial cells of the hippocampus and cerebellum 
participate in synaptic transmission, regulate the clearance of neurotransmitters from the 
synaptic cleft, release factors such as ATP, which modulate presynaptic function, and 
even release neurotransmitters themselves.  
 Traditionally glia has been considered to lack certain features of neurons. For 
example, glial cells were not believed to have chemical synapses (see Chapter 2.1.3.6) 
or to release neurotransmitters (see Chapter 2.3). They were considered to be the 
passive bystanders of neural transmission. However, recent studies have shown this to 
be untrue. For example, astrocytes are crucial in clearance of neurotransmitter from 
within the synaptic cleft, which provides distinction between arrival of action potentials 
(see Chapter 2.2.1.3.) and prevents toxic build up of certain neurotransmitters such as 
glutamate (excitotoxicity). Furthermore, at least in vitro, astrocytes can release 
neurotransmitter glutamate in response to certain stimulation.  
 The only notable differences between neurons and glial cells are neurons' 
possession of axons and dendrites, and capacity to generate action potentials. 
 Glia ought not to be regarded as 'glue' in the nervous system as the name 
implies; rather, it is more of a partner to neurons. They are also crucial in the 
development of the nervous system and in processes such as synaptic activity and 
synaptogenesis. Glia has a role in the regulation of repair of neurons after injury. In the 
CNS, glia suppresses repair. Glial cells known as astrocytes enlarge and proliferate to 
form a scar and produce inhibitory molecules that inhibit regrowth of a damaged or 
severed axon. (Levitan & Kaczmarek, 1997) 
Shortly, there are a number of functional roles ascribed to glia: 
 myelination 
 act as a scaffolding for neuronal migration and axon outgrowth 
 participate in the uptake and metabolism of the neurotransmitters that neurons 
use for intercellular communication 
 take up and buffer ions from the extracellular environment 
 act as scavengers to remove debris produced by dying neurons 
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Although the evidence is less definitive, glia also may: 
 segregate groups of neurons one from another, and act as a electrical insulators 
between neurons 
 provide structural support for neurons, fulfilling a role played by connective 
tissue cells in other organs 
 play a nurturing role, supplying metabolic components and even proteins 
necessary for neuronal functions 
 play a role in information handling and memory storage 
 
 
 
Figure 2.2: Glial cells (Image 2) 
  
 
2.1.2  TYPES OF GLIAL CELLS IN CENTRAL NERVOUS SYSTEM 
 
 Glial cells can themselves be divided into several subclasses based on their 
appearance in the microscope. We have more types of glial cells surrounding neurons, 
microglial and macroglial cells. In the CNS, there are two main types of glial cells, 
astrocytes and oligodendrocytes. (Pelvig et al., 2008) 
2.1.2.1  ASTROCYTES 
 The most abundant type of macroglial cell, astrocytes (also called astroglia), 
have numerous projections that anchor neurons to their blood supply. They regulate the 
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external chemical environment of neurons by removing excess ions, notably potassium, 
and recycling neurotransmitters released during synaptic transmission (Pelvig et al., 
2008). Astrocytes are believed to play an important role in the volume changes of the 
nervous tissue a key component of changing optical properties (Konopková, 2004).  
 
2.1.2.2  OLIGODENTROCYTES 
 
 Oligodendrocytes are cells that coat axons in CNS with their cell membrane 
forming a specialized membrane differentiation called myelin, producing the so-called 
myelin sheath. The myelin sheath provides insulation to the axon that allows electrical 
signals to propagate more efficiently. (Pelvig et al., 2008) 
 
2.1.2.3  EPENDYMAL CELLS 
 
 Ependymal cells, also named ependymocytes, line the cavities of the CNS and 
make up the walls of the ventricles. These cells create and secrete cerebrospinal fluid 
(CSF) and beat their cilia to help circulate CSF. (Pelvig et al., 2008) 
 
2.1.2.4  RADIAL GLIA 
 
 Radial glia cells arise from neuroepithelial cells after the onset of neurogenesis. 
Their differentiation abilities are more restricted than those of neuroepithelial cells. In 
the developing nervous system, radial glias function both as neuronal progenitors and as 
a scaffold upon which newborn neurons migrate. (Pelvig et al., 2008) 
 
2.1.3  NEURON´S STRUCTURE 
 
 Neurons have structures and organelles that are in common with other cells. The 
most prominent organelle in the cell body is the nucleus, which contains the genetic 
material, DNA. The entire neuron is enclosed by a plasma membrane. This is a double 
layer of phospholipid molecules, which acts as a barrier preventing the contents of the 
cell from mixing with those of the extracellular space. It is also an effective electrical 
insulator, hindering the diffusion of charged ions in and out of the cell. Signaling in 
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nerve cells requires the controlled movement of ions across the plasma membrane, a 
process mediated by specialized proteins located in the membrane. The cell body 
contains mitochondria (see Chapter 2.1.3.1) to supply the cell’s energy needs. In fact, 
because a great deal of energy is required to maintain the transmembrane ionic gradients 
that are essential for neuronal signaling, neurons tend to be particularly rich in 
mitochondria. There are also ribosomes, which are responsible for the synthesis of 
proteins destined for insertion into membranes, or for secretion; they are located on the 
membranous sacs of the rough endoplasmatic reticulum. Other membranous 
components include the smooth endoplasmatic reticulum and the Golgi complex, 
involved in the processing of proteins for membrane insertion or secretion, and 
lysosomes and other granules involved in the break-down and disposal of cellular 
components. 
 
2.1.3.1  MITOCHONDRIA 
 
 Mitochondria are sometimes described as “cellular power plants” because they 
generate most of the cell's supply of adenosine triphosphate (ATP), used as a source of 
chemical energy. In addition to supplying cellular energy, mitochondria are involved in 
a range of other processes, such as signaling, cellular differentiation, cell death, as well 
as the control of the cell cycle and cell growth. 
 This organelle is composed of compartments that carry out specialized functions. 
These compartments include the outer membrane, the intermembrane space, the 
inner membrane, and the cristae and matrix. 
 The most prominent roles of mitochondria are to produce energy in form of 
ATP (i.e., phosphorylation of ADP) through respiration, and to regulate cellular 
metabolism. The central set of reactions involved in ATP production is collectively 
known as the citric acid cycle, or the Krebs Cycle; and respiratory chain (Bruce et al., 
1994) 
 But there are three structural elements unique to neurons, the axon (see Chapter 
2.1.3.2), which is specialized for intracellular information transport, the dendrite (see 
Chapter 2.1.3.3), which is often the site at which information is received from other 
neurons, and the most highly specialized structure of all, the synapse (see Chapter 
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2.1.3.4), which is the point of information transfer between neurons (see Fig. 1.1). 
(Levitan & Kaczmarek, 1997) 
 
2.1.3.2  AXONS 
 
 Axon is a long, slender projection of neuron that conducts electrical impulses 
away from the neuron's cell body. It originates at a cone-shaped thickening on the cell 
body called the axon hillock. Axon’s structure is formed and maintained by the 
cytoskeleton. (Levitan & Kaczmarek, 1997) 
 
2.1.3.3  DENDRITES 
 
 Dendrites are neuronal processes that tend to be thicker and much to be shorter 
than axons and they are often highly branched, giving rise to a dense network of 
processes known as the dendritic tree. There is a presence of numerous finger-like 
projections or thickenings on the dendrites of some neurons. These projections, called 
dendritic spines, arise from the main shaft of the dendrite. These spines are the synaptic 
input sites at which the neuron receives information from another cell. However, the 
role of the dendrite is not exclusively the receipt of information. Some dendrites share 
with axons the ability to transmit electrical signals, and in many nerve cells both 
information input and output occur on the same set of dendrite-like fine processes. 
(Levitan & Kaczmarek, 1997) 
 
2.1.3.4  SYNAPSES 
 
 Intercellular communication means the passage of information from one part of 
the nervous system to another and it is the essence of nervous system function. This 
information transfer distinguishes the brain from other organs and the synapse carries 
out this task (Levitan & Kaczmarek, 1997). The adult human brain is estimated to 
contain from 1014 to 5 × 1014 (100-500 trillion) synapses. Every cubic millimeter of 
cerebral cortex contains roughly a billion of them (Alonso-Nanclares, 2008). 
 At a synapse, the plasma membrane of the signal-passing neuron (the 
presynaptic neuron) comes into close apposition with the membrane of the target 
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(postsynaptic) cell. Both the presynaptic and postsynaptic sites contain extensive arrays 
of molecular machinery that link the two membranes together and carry out the 
signaling process. (Rapport, 2005) 
 There are two different types of synapse: 
Electrical synapse. The presynaptic and postsynaptic cell membranes are connected by 
channels that are capable of passing electrical current, causing voltage changes in the 
presynaptic cell to induce voltage changes in the postsynaptic cell. (Rapport, 2005) 
Chemical synapse. The presynaptic neuron releases a chemical called a 
neurotransmitter that binds to receptors located in the postsynaptic cell, usually 
embedded in the plasma membrane. Binding of the neurotransmitter to a receptor can 
affect the postsynaptic cell in a wide variety of ways. (Rapport, 2005) 
 
2.1.3.5  ELECTRICAL SYNAPSE 
 
  Signals can move in both directions through electrical synapses, it is 
bidirectional information transfer. Between the membranes of the pre- and postsynaptic 
cells are found gap junctions, cell-to-cell pores that allow ions and small molecules to 
pass freely from the cytoplasm of one cell to the next. This movement mediates 
intercellular signaling in electrical synapses. (Levitan & Kaczmarek, 1997) 
Compared to chemical synapses, electrical synapses conduct nerve impulses 
faster, but unlike chemical synapses they do not have gain (the signal in the post 
synaptic neuron is always smaller than that of the originating neuron).  
 The response is always the same sign as the source. For example, depolarization 
(see Chapter 2.2.1.3) of the pre-synaptic membrane will always induce a depolarization 
in the post-synaptic membrane, and vice versa for hyperpolarization. (Purves et al., 
2008) 
2.1.3.6  CHEMICAL SYNAPSE 
 The presynaptic ending is swelling of the axon terminal, containing 
mitochondria and, the most important, a variety of vesicular structures. The pre- and 
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postsynaptic elements are separated by a gap, the synaptic cleft (Levitan & Kaczmarek, 
1997). Synaptic vesicles are docked at the presynaptic plasma membrane at regions 
called active zones. Opposite is a region of the postsynaptic cell containing 
neurotransmitter receptors. Most synapses connect axons to dendrites, but there are also 
other types of connections, including axon-to-cell-body, axon-to-axon, and dendrite-to-
dendrite (Weiss et al., 1994). 
 Chemical synapses are unidirectional. It means that rapid transfer of information 
only occurs from the pre- to postsynaptic cell. There is a delay that may be a 
millisecond or longer between the arrival of information at the presynaptic terminal and 
its transfer to the postsynaptic cell. (Levitan & Kaczmarek, 1997) 
 
2.1.4  HIPPOCAMPUS 
 
2.1.4.1  HUMAN 
 
 The hippocampus is a major component of the brains of humans and other 
mammals. It belongs to the limbic system and plays important roles in long term 
memory and spatial navigation. There is evidence that the hippocampus plays a role 
in finding shortcuts and new routes between familiar places. Like the cerebral cortex, 
with which it is closely associated, it is a paired structure, with mirror-image halves in 
the left and right sides of the brain. (Amaral & Lavemex, 2006) 
 Hippocampus processes information from cerebral cortex and limbic system and 
then it transfer information into anterior thalamus, hypothalamus and other parts of 
brain. Most of these information return to cerebral cortex. This rhythmic excitatory 
activity is a base of complex integrative processes as loading information into the long-
term memory. 
 In Alzheimer’s disease, the hippocampus is one of the first regions of the brain 
to suffer damage; memory problems and disorientation appear among the first 
symptoms. Damage to the hippocampus can also result from oxygen starvation 
(hypoxia), encephalitis, or medial temporal lobe epilepsy. (Best & White, 1999) 
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2.1.4.2  RAT 
 
 Hippocampal formation is a useful model for the study of properties of central 
nervous system because of its unidirectional connectivity, similarity to the human 
structure and very well known morphology. (Amaral & Witter, 1995) 
 Hippocampal formation of the rat with its surface area approximately 1.2cm2 
(the surface of the entire isocortex is estimated with 1.5cm2) is a prominent component 
of the rat nervous system and attracts the attention of neuroanatomists since the 
beginning of formal study of the nervous system. (Amaral & Witter, 1995) 
 The hippocampus as a whole has the shape of a curved tube, which has been 
analogized variously to a seahorse, a ram's horn (Cornu Ammonis - Ammons Horn - 
CA). It consists of ventral and dorsal portions, both of which share similar composition 
but are parts of different neural circuits. This general layout holds across the full range 
of mammalian species, from hedgehog to human, although the details vary. (Amaral & 
Lavemex, 2006) 
 The hippocampal formation includes the entorhinal cortex (EC); dentate gyrus 
(DG); hippocampus proper, which is subdivided into fields CA1, CA2, and CA3 
(although the existence of CA2 in the rat is controversial and rarely mentioned in the 
physiology literature); and the subicular complex, consisting of the subiculum, 
presubiculum, and parasubiculum. (Amaral & Witter, 1995) 
 Dentate gyrus (DG) contains three layers, molecular layer (contains dendrites 
of granule cells, basket and polymorphic cell, axonal arbors); the granule cell layer 
(principal cell layer) which is made up primarily of densely packed columnar stacks of 
granule cells; the polymorphic cell layer (mossy cells). (Amaral & Witter, 1995) 
 Many neurons in the rat and mouse hippocampus respond as place cells: that is, 
they fire bursts of action potentials when the animal passes through a specific part of its 
environment. Hippocampal place cells interact extensively with head direction cells, 
whose activity acts as an inertial compass, and with grid cells in the neighboring 
entorhinal cortex. 
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2.1.4.3  TRISYNAPTIC CIRCUIT  
  
 The perforant path-to-dentate gyrus-to-CA3-to-CA1 was called the trisynaptic 
circuit by Per Andersen, who noted that thin slices could be cut out of the hippocampus 
perpendicular to its long axis, in a way that preserves all of these connections. This 
observation was the basis of his lamellar hypothesis, which proposed that the 
hippocampus can be thought of as a series of parallel strips, operating in a functionally 
independent way. (Andersen et al., 1971) 
 The hippocampus forms a principally unidirectional network with input from the 
entorhinal cortex (EC) that forms connections with the dentate gyrus (DG) and CA3 
pyramidal neurons via the Mossy fibers (MF). They send axons to CA1 pyramidal cells 
via the Schaffer collateral pathway (SC), as well as to CA1 cells in the contralateral 
hippocampus via the associational commissural pathways (AC). CA1 neurons also 
receive input directly from the perforant path and send axons to the Subiculum (Sb). 
These neurons in turn send the main hippocampal output back to the EC, forming a 
loop.   
 
 
Figure 2.3: Trisynaptic circuit (Image 3)                                                             
(AC = associational commissural pathways; EC = entorhinal cortex; DG = dentate 
gyrus; PP = perforant pathway - medial or lateral; MF = Mossy fibers; SC = Schaffer 
collaterals) 
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2.2  ELECTROPHYSIOLOGY 
 
 
2.2.1  ELECTRICAL SIGNALING IN NEURONS 
 
 Neurons, like all other cells, exhibit a voltage difference known as the 
membrane potential across their plasma membranes. This potential results from the 
unequal distribution of electrical charge, carried by ions (potassium, sodium, calcium 
and chloride), on two sides of the membrane. Some ions can move across the plasma 
membrane more readily than the others and such differential permeability arises because 
of the presence of specialized proteins known as ion channels. (Levitan & Kaczmarek, 
1997) 
 
2.2.1.1  ION CHANNELS 
 
 Ion channels are integral membrane proteins with a pore through which ions can 
travel between extracellular and intracellular space. Most channels are specific 
(selective) for one ion, especially potassium and sodium channels are very selective for 
their proteins. Ion channels may have different states (corresponding to different 
conformations of the protein), but each state is either open or closed. They can be 
classified by the nature of their gating, so that by their response to the environment; 
voltage-gated channels and ligand-gated channels. 
 Voltage-gated channels open and close in response to the voltage across the 
membrane, they have a crucial role in excitable neuronal tissue, allowing a rapid and 
coordinated depolarization. For example, voltage-gated calcium channels play an 
important role in neurotransmitter release in pre-synaptic nerve endings. Ligand-gated 
channels form another important class, opened and closed in response to the binding of 
a ligand molecule, such as neurotransmitter. Such receptors located at synapses convert 
the chemical signal of presynaptically released neurotransmitter directly and very 
quickly into a postsynaptic electrical signal. 
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2.2.1.2  RESTING POTENTIAL 
 
 The resting potential is usually in the range –40 to –90mV, in most neurons of 
human body it balanced -70 to -90mV.  This negative membrane potential indicates that 
the inside of the cell membrane is more negative than the outside. When the membrane 
potential is less negative than the resting potential, the cell is said to be depolarized; 
when it is more negative, the cell is hyperpolarized. (Levitan & Kaczmarek, 1997) 
 The cell membrane prevents charged particles such as mentioned ions from 
freely diffusing into and out of the cell. There are two basics ways that they can get in 
or out. The first is with passive transport. Basically the cell has a protein, called ion 
channels and mentioned above, in the cell membrane that it can open and close like a 
water faucet. It is specific for certain kinds of chemicals like these ions. When it opens, 
then the ions can flow down their gradient from the more concentrated area to the less 
concentrated area. The other way to get ions in or out of cells is to by active transport. 
The cell uses some of its own energy, represented by ATP, to actively pump the 
chemicals against their gradient. The neuron has an ion pump, Na+/K+-ATPase also 
called sodium-potassium pump, that actively pumps three Na+ ions out and takes in 
two K+ ions. This means that a net positive charge flows out of the neuron. This is what 
gives the cell its negative potential. 
 
2.2.1.3  ACTION POTENTIAL 
 
 An action potential (AP) is a short-lasting event in which the electrical 
membrane potential of a cell rapidly rises and falls, following a stereotyped trajectory. It 
plays a central role in cell-to-cell communication. (Barnett & Larkman, 2007) 
 As the depolarizing stimulus gets larger, a critical stimulus strength or threshold 
is reached. This active response of the membrane when the depolarization exceeds 
threshold is the nerve impulse or action potential. The threshold is essential to ensure 
that small random depolarization of the membrane do not generate APs. Only stimuli of 
sufficient importance (reflected by their larger amplitude); result in information transfer 
via AP. Another important property of APs is that they are all-or-none events; this all-
or-none law is an essential feature of axonal signaling transmission. Once the stimulus 
is above threshold, the amplitude of the response no longer reflects the amplitude of the 
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stimulus. It means that information about stimulus strength must be represented, 
encoded, in the axon in some way other than action potential amplitude; the amplitude 
of the AP is generally independent of stimulus intensity. The latency, the time delay 
from the onset of the stimulus to the peak of the AP, is a function of stimulus strength. 
The stronger stimulus the shorter delay between stimulus and AP. For several 
milliseconds after the firing of AP, it is impossible to evoke another AP no matter how 
large the depolarizing stimulus. The axon is refractory to stimuli during this time, so it 
is called refractory period. This absolute refractory period is followed by a relative 
refractory period, during which the stimulus must be larger than normal to evoke an AP. 
During the absolute refractory period the threshold is essentially infinite, and no 
stimulus, no matter how large, can exceed it. During the relative refractory period the 
threshold is larger than normal, that is, it requires a larger than normal stimulus to 
exceed it (Levitan & Kaczmarek, 1997). In summary we can say about electrical 
signaling in neurons that: 
 there is a threshold for generation of AP that guarantees that small random 
variations in the membrane potential are not misinterpreted as meaningful 
information; 
 the all-or-none law guarantees that once an AP is generated, it is always full 
size, minimizing the possibility that information will be lost along the way; 
 the strength-latency relationship and the refractory period, together with the 
threshold, allow the encoding of information in the form of a frequency code; 
and 
 the phenomenon of passive spread, which arises simply from the cable-like 
properties of the axonal membrane, allows the propagation of action potentials 
along the axon and the transfer of information over long distance within the 
neuron. 
 The course of the AP can be divided into five parts: the rising phase, the peak 
phase, the falling phase, the undershoot phase, and finally the refractory period. 
During the rising phase the membrane potential depolarizes (becomes more positive), it 
is also called depolarization. The point at which depolarization stops is called the peak 
phase. At this stage, the membrane potential reaches a maximum. Subsequent to this, 
there is a falling phase. During this stage the membrane potential hyperpolarizes 
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(becomes more negative), also called repolarization. When repolarization is about 70% 
completed, the rate of repolarization decreases and the curve approaches the resting 
level more slowly. The sharp rise and rapid fall are the spike potential of the neuron, 
and the slower fall at the end of the process is the after-depolarization. The undershoot 
phase, also called hyperpolarization, is the point during which the membrane potential 
becomes temporarily more negatively charged than when at rest. Finally, the time 
during which a subsequent action potential is impossible or difficult to fire is called the 
refractory period, also called after-hyperpolarization, which may overlap with the 
other phases (see Fig. 2.4). (Purves et al., 2008) 
 
 
        
Figure 2.4: Action potential and its phases (Image 4) 
 
 
 Ions are also responsible for the initiation or transmission of AP in the neurons, 
like in the case of resting potential. Ion flow in and out of the cell becomes in few steps 
(see Fig. 2.5): 
1. The first step of AP is that the Na+ channels open allowing a flood of sodium 
ions into the cell. This causes the membrane potential to become positive. 
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2. At some positive membrane potential the K+ channels open allowing the 
potassium ions to flow out of the cell. 
3. Next the Na+ channels close. This stops inflow of positive charge. But since the 
K+ channels are still open it allows the outflow of positive charge so that the 
membrane potential plunges. 
4. When the membrane potential begins reaching its resting state the K+, channels 
close. 
5. Now the sodium-potassium pump does its work and starts transporting sodium 
out of the cell, and potassium into the cell so that it is ready for the next AP. 
 
 
 
Figure 2.5: Action potential and ion flow (Image 5) 
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2.3 NEUROTRANSMITTERS IN CNS 
 
 
 Neurotransmitters are endogenous chemicals, which relay, amplify, and 
modulate signals between a neuron and another cell. Major neurotransmitters in CNS 
include amino acids such as glutamate (see Chapter 2.3.4), aspartate, serine, -
aminobutyric acid (GABA) (see chapter 2.3.3), glycine; monoamines such as dopamine, 
noradrenaline, adrenaline, histamine, serotonin, melatonin; and many others like an 
acetylcholine, over 50 neuroactive peptides, single ions, such as synaptically released 
zinc and a few gaseous molecules such as nitric oxide (NO) and carbon monoxide (CO).  
 Description of all neurotransmitters is over the range of this thesis so for their 
connectivity in epileptiform seizures and research; and a role in function and synthesis 
of NO in CNS (see Chapter 2.4.3.), following list include two major representatives; 
inhibitory GABA and excitatory glutamate.  
 
2.3.1  NEUROTRANSMITTER RELEASE AND RECEPTOR 
          BINDING 
 
 The process begins with a wave of electrochemical excitation called an action 
potential traveling along the membrane of the presynaptic cell, until it reaches the 
synapse. The electrical depolarization of the membrane at the synapse causes channels 
to open that are permeable to calcium ions. Calcium ions then trigger a biochemical 
cascade that results in vesicles fusing with the presynaptic membrane and releasing their 
contents to the synaptic cleft within 180µsec of calcium entry. (Llinás et al., 1981) 
 Receptors on the opposite side of the synaptic gap bind neurotransmitter 
molecules and respond by opening nearby ion channels in the postsynaptic cell 
membrane, causing ions to rush in or out and changing the local transmembrane 
potential of the cell. The resulting change in voltage is called a postsynaptic potential. 
In general, the result is excitatory, in the case of depolarizing currents, or inhibitory in 
the case of hyperpolarizing currents. Whether a synapse is excitatory or inhibitory 
depends on what type(s) of ion channel conduct the postsynaptic current display(s), 
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which in turn is a function of the type of receptors and neurotransmitter employed at the 
synapse. (Llinás et al., 1981) 
 
2.3.2  AGONIST AND ANTAGONIST 
 
 Receptors can be activated or inactivated by either endogenous (such as 
hormones and neurotransmitters) or exogenous (such as drugs) agonists and antagonists, 
resulting in stimulating or inhibiting a biological response. 
 An agonist is a chemical that binds to a receptor of a cell and triggers a response 
by the cell. An agonist often mimics the action of a naturally occurring substance. 
 A receptor antagonist is a type of receptor ligand or drug that does not provoke 
a biological response itself upon binding to a receptor, but blocks or reduces agonist-
mediated responses. In pharmacology, antagonists have affinity but no efficacy for their 
cognate receptors, and binding will disrupt the interaction and inhibit the function of an 
agonist or inverse agonist at receptors. (Kenakin, 2006) 
 
2.3.3  GABA  
 
 GABA (γ-aminobutyric acid) is the chief inhibitory neurotransmitter in the 
central nervous system. It acts at inhibitory synapses in the brain by binding to specific 
transmembrane receptors in the plasma membrane of both pre- and postsynaptic 
neuronal processes. This binding causes the opening of ion channels to allow the flow 
of either negatively charged chloride ions into the cell or positively charged potassium 
ions out of the cell. This action results in a negative change in the transmembrane 
potential, usually causing hyperpolarization. Two general classes of GABA receptor are 
known: GABAA in which the receptor is part of a ligand-gated ion channel complex, 
and GABAB metabotropic receptors, which are G protein-coupled receptors that open or 
close ion channels via intermediaries (G proteins). Neurons that produce GABA as their 
output are called GABAergic neurons. 
GABAA receptors are chloride channels. It means that when activated by 
GABA, they allow the flow of chloride ions across the membrane of the cell. Whether 
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this chloride flow is excitatory - depolarizing (makes the voltage across the cell's 
membrane less negative), shunting (has no effect on the cell's membrane) or inhibitory - 
hyperpolarizing (makes the cell's membrane more negative) depends on the direction of 
the flow of chloride. When net chloride flows out of the cell, GABA is excitatory or 
depolarizing; when the net chloride flows into the cell, GABA is inhibitory or 
hyperpolarizing. When the net flow of chloride is close to zero, the action of GABA is 
shunting. (Watanabe et. al., 2002) 
Drugs that act as agonists of GABA receptors (known as GABAergic drugs) or 
increase the available amount of GABA typically have relaxing, anti-anxiety and anti-
convulsive effects. Antagonists of GABA, such as Bicuculline (see Chapter 2.7.4.7) 
play an opposite role and block their inhibitory action. 
 
2.3.4  GLUTAMATE 
 
 Glutamate is a non-essential amino acid. It is the most abundant excitatory 
neurotransmitter in the nervous system. At chemical synapses, glutamate is stored in 
vesicles. Nerve impulses trigger release of glutamate from the pre-synaptic cell. In the 
opposing post-synaptic cell, glutamate receptors, such as the NMDA receptors (see 
Chapter 2.3.5.), bind glutamate and are activated. Because of its role in synaptic 
plasticity, glutamate is involved in cognitive functions like learning and memory in the 
brain, this process is called neuroplasticity (see Chapter 2.6). (McEntee & Crook, 1993) 
Glutamate is also responsible for PDS (see Chapter 2.7.5) behaviour that is recorded 
intracellulary in association with epileptic discharges.  
 Glutamate receptors can be divided into two groups according to the 
mechanism by which their activation gives rise to a postsynaptic current. Ionotropic 
glutamate receptors (NMDA, AMPA and kainate receptor) form the ion channel pore 
that activates when glutamate binds to the receptor. Metabotropic glutamate receptors 
(mGluR) indirectly activate ion-channels on the plasma membrane through a signaling 
cascade that involves G proteins. Ionotropic receptors tend to be quicker in relaying 
information but metabotropic are associated with a more prolonged stimulus. (Palmada 
& Centelles, 1998) 
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2.3.5  NMDA RECEPTORS 
 
NMDA receptor is a specific type of ionotropic glutamate receptor. NMDA (N-
methyl D-aspartate) is the name of an agonist that binds to NMDA receptors but not to 
other glutamate receptors. Activation of NMDA receptors results in the opening of an 
ion channel that is nonselective to cations. A unique property of the NMDA receptor is 
its voltage-dependent activation, a result of ion channel block by extracellular Mg2+ 
ions. This allows voltage-dependent flow of Na+ and small amounts of Ca2+ ions into 
the cell and K+ out of the cell. Calcium flux through NMDA receptors is thought to play 
a critical role in synaptic plasticity (see Chapter 2.6), a cellular mechanism for learning 
and memory.  
With regard to synaptic plasticity, the role of the NMDA receptor is best 
described as coincidence detection. It means that only if both the pre- and postsynaptic 
cells are simultaneously active will NMDA receptors become unblocked and allow 
calcium ions to enter the postsynaptic cell. Thus, the NMDA receptor converts an 
electrical signal into a biochemical signal that can trigger synaptic plasticity.  
NMDA receptors are modulated by a number of endogenous and exogenous 
compounds and play a key role in a wide range of physiologic and pathologic processes, 
such as excitotoxicity, pathological process where nerve cells are damaged and killed by 
glutamate and similar substances, so they play an important role in neurological 
disorders such as stroke, traumatic brain injury or epilepsy. (Liu & Zhang, 2000) 
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2.4  NITRIC OXIDE 
 
 
 Nitric oxide (NO) is a gaseous free radical synthesized from L-arginine in 
several mammalian cells by the enzyme nitric oxide synthase (NOS) and is known as a 
neuronal messenger. (Schuchmann et al., 2002) 
 The physical properties of NO prevent its storage in lipid-lined vesicles and 
metabolism by hydrolytic depredatory enzymes. NO is synthesized on demand and is 
neither a stored in synaptic vesicle nor release by exocytose, but simply diffuses from 
nerve terminals. (Esplugues, 2002) 
 
 
2.4.1  HISTORY  
 
 The discovery of the biological functions of NO in the 1980s came as a complete 
surprise and caused quite a stir. NOS was first identified and described in 1989, its three 
major isoforms were cloned and purified between 1991 and 1994, and in 1994 there 
were several reviews of the work on these enzymes until this time. Then “NO and NOS 
boom” started in publishing and research, including a great deal on the structure, 
function and inhibition of the enzymes. Nitric oxide was named "Molecule of the Year" 
in 1992 by the journal Science, a Nitric Oxide Society was founded, and a scientific 
journal devoted entirely to nitric oxide was established. 
 The first X-ray crystal structures of NOS domains have been presented and 
published in 1998 and 1999; and the importance of the field of nitric oxide research was 
recognized in 1998 by the award of the Nobel Prize to R. Furchgott, L. Ignaro and F. 
Murad for the work that led to the discovery of NO as a biological mediator produced 
by mammalian cells. (Alderton et al., 2001) 
 It is estimated that yearly about 3,000 scientific articles are published on the 
biological roles of NO what makes this molecule one of the most discussed theme in 
physiology, pharmacology and other research branches. 
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2.4.2  NITRIC OXIDE SYNTHASE (NOS) 
 
 Control of the synthesis of NO is the key to regulating its activity. There are 
three known isoforms of NOS and each of them has its specific function in human body. 
Endothelial NOS (eNOS) and inducible NOS (iNOS) are present in the nervous system. 
Neuronal NOS (nNOS) is the principal isoform present in said system (Esplugues, 
2002). Some authors (Lamas & Cadenas, 2006) describe the fourth type of this enzyme, 
so extended of mitochondrial NOS (mtNOS) as a subtype of nNOS which has an 
important role in intracellular signaling and apoptosis, cellular death.  
 nNOS and eNOS are the constitutive calcium-dependent and produce low levels 
of gas as a cell signaling molecule, whereas iNOS is calcium-independent and produces 
large amounts of gas which can be cytotoxic. (Esplugues, 2002) 
 eNOS is originally found in the endothelial cells that line the lumen of blood 
vessels and the specific function of NO synthesized by this enzyme is vasodilatation. 
iNOS is originally found in macrophages, a cell acting in both non-specific and specific 
defense, and its function is specialized in immune defense against pathogens. Whereas 
the levels of eNOS and nNOS are relatively steady, expression of iNOS genes awaits an 
appropriate stimulus (e. g., ingestion of a parasite). nNOS produces NO in nervous 
tissue in both the central and peripheral nervous system. It performs a role in cell 
communication and is associated with plasma membranes. All types of NOS produce 
NO from L-arginine; α-amino acid ideal for binding negatively charged groups as 
proteins; with the aid of molecular oxygen and NADPH (α-nicotinamide adenine 
dinucleotide phosphate) which provides the reducing equivalents for biosynthetic 
reactions and anabolic pathways, such as lipid synthesis, cholesterol synthesis or 
glucose synthesis. 
 nNOS-containing neurons are presented in many areas of the CNS with the 
highest densities occurring in the accessory olfactory bulb and granule cells of the 
cerebellum. nNOS can be located either pre- or post-synaptically and is particularly 
implicated in neural signaling, neurotoxicity, synaptic plasticity and modulation of 
behavioral pathways such as learning or expression of pain. (Esplugues, 2002) eNOS is 
mainly involved in the regulation of vascular function and, although also present in 
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some populations of neurons (Dinerman et al., 1994) and glia (Wiencken & Casagrande, 
1999), is predominantly located in the endothelial cells of cerebral vessels. Finally, 
induction of iNOS in glial cells is implicated in the unspecific immune response of the 
brain and is usually associated with pathological conditions (Murphy, 2000). 
 The aim of this thesis is to introduce a role of NO in CNS, respectively the 
research in vitro in the nervous tissue, so the text below is also aimed on all relative in 
this tissue, so that mostly in nNOS. Description of other forms of NOS and produced 
NO by themselves rounds off the idea about the functioning of CNS as a complex, 
including vascular, immune and other support for its function.   
 
 2.4.3  REGULATION OF nNOS 
 
Figure 2.6: NO synthesis 
(Image 6) 
 
For our purpose is sufficient 
to know that release of 
glutamate activates NMDA 
receptors and the 
consequence flux of Ca2+ 
entering the ion channel 
activates nNOS. It is 
possible that NO bioactivity 
feeds back to control the 
presynaptic neuron and the 
activity of the channel. Just 
for an entire explanation of 
the image, PSD-95 is 
postsynaptic density protein 
and CAPON is a protein 
associated with nNOS and 
regulation of NO formation 
in neurons. (Esplugues, 
2002) 
 
 
Note: L-Arg (L-Arginine); CaM 
(calmodulin); Glu (glutamate); 
nNOS (neuronal NO synthase); 
NMDAr (NMDA receptor) 
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 The most important regulator of nNOS activity seems to be free cystolic Ca2+, 
which stimulates nNOS through interaction with calmodulin, calcium-binding protein. 
Arrival of action potentials activates voltage-dependent Ca2+ channels situated in the 
neurolemma, and stimulates the release of Ca2+ from intracellular stores. This elevates 
cytosolic Ca2+ concentrations above the 400 nM required for calmodulin to bind to 
nNOS, thereby activating the enzyme. When the concentration of Ca2+ falls, it 
dissociates from the calmodulin, which in turn dissociates from the nNOS, thus 
activating as a switch that turns the enzyme on and off. This process occurs in the 
majority of peripheral and in some central nitrergic neurones. However, in the CNS, NO 
synthesis seems predominantly regulated by the influx of Ca2+ through receptor-
dependent channels, in particular following postsynaptic stimulation of NMDA 
receptors by the excitatory neurotransmitter, glutamate (see Fig. 2.6). (Bredt & 
Snyder, 1989; Garthwaite et al., 1989) 
 
2.4.4  NITRIC OXIDE IN MITOCHONDRIA 
 
 As mentioned above, mitochondria are the important parts of every neuron 
because they take place in processing of oxygen and production of energy in respiratory 
chain and Krebs cycle. There is an evidence that NO modulates oxygen consumption in 
the mitochondria. In particular, nanomolar concentrations of NO inhibit cytochrome 
oxidase, the terminal hem-containing enzyme in the mitochondrial respiratory chain. 
Recent evidence demonstrates that this effect is reversible and competitive with oxygen, 
and suggests that NO is a crucial regulator in the generation of energy and the mediation 
of cell death by mitochondria. (Beltrán et al., 2000) 
 
2.4.5  NITRIC OXIDE IN CENTRAL NERVOUS SYSTEM 
 
 NO is known as a neurotransmitter between nerve cells in CNS. Unlike most 
other neurotransmitters that only transmit information from a presynaptic to a 
postsynaptic neuron, the small, uncharged, and fat-soluble nitric oxide molecule can 
diffuse widely and readily enters cells. Thus, it can act on several nearby neurons, even 
on those not connected by a synapse. 
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 NO has been proposed as the retrograde messenger which co-ordinates the 
enhancement of both pre- and post-synaptic mechanism involved in two forms of 
synaptic plasticity; namely long-term potentiation (see Chapter 2.6.1) and long-term 
depression (see Chapter 2.6.2). (Esplugues, 2002) 
 NO has been linked to the release of other neurotransmitters and the effects 
which they produce, in particular acetylcholine, noradrenaline, dopamine, glutamate, γ-
aminobutyric acid (GABA), serotonin, adenosin triphosphate (ATP), carbon monoxide 
and opioids. (Esplugues, 2002) 
 It has been suggested that NO modulates gene transcription and translation in 
neurones and glia. (Esplugues, 2002) 
 
2.4.5.1  SYSTEMIC EFFECT 
 
 NO has the complex influences on brain development, memory formation and 
behavior through regulation of synaptic plasticity.  
 Inhibition of NO synthesis produces amnesia (Holscher & Rose, 1992), disrupts 
spatial learning and olfactory memory (Bohme et al., 1993), blunts behavioral 
performance during task acquisition, and decreases locomotor’s activity in habituation 
tasks (Yamada et al., 1995). NO has also been implicated in neuronal targeting and 
brain development (Contestabile, 2000), visual processing (Cudeiro & Rivadulla, 1999), 
discriminative learning (Groll-Knapp et al., 1988), food and drinking behavior (Calapai 
et al., 1992), thermoregulation (De Luca et al., 1995), opiate tolerance and withdrawal 
(Mao, 1999), circadian rhythm (Watanabe et al., 1995), sleep (Kapas et al., 1994) and 
respiratory pattern (Ling et al., 1992). 
 There is an ever-growing list of peripheral functions in which a role for central 
NO has been proposed (Esplugues, 2002). There is evidence implicating central NO in 
the regulation of blood pressure (Togashi et al., 1992), heart rate (Sakuma et al., 1992), 
stimulated renal sympathetic nerve activity (Sakuma et al., 1992), gastric acid secretion 
(Esplaques et al., 1996) and motility and motor disruption associated with alcohol abuse 
(Sandor et al., 1995). Likewise, NO in the CNS appears to be involved in reflexes 
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leading to a diminished sympathetic output to the periphery and the modulation of 
various neuroendocrine responses (Esplugues, 2002). 
 
2.4.5.2  ROLE IN PERCEPTION OF PAIN 
 
 NO has been implicated at various levels of the nociceptive neural pathways, 
both peripherally and centrally (Mao, 1999). It is established that synthesis of NO 
enhances spinal facilitation of the afferent input conveyed to the cortex and 
subsequently manifested in behavioral responses (Mayer et al., 1999). However the role 
of NO changes according to the pain stimuli. Inhibition of NO has antinociceptive 
effects (Kitto et al., 1992) and in contrast, blockade of NO synthesis exacerbates pain in 
models of mechanical hyperalgesia (Zhuo et al., 1993).  
 
2.4.5.3  ROLE IN NEURONAL DAMAGE AND PROTECTION 
 
 The neuronal damage that accompanies cerebral ischemia involves and 
excessive release of glutamate and a subsequent activation of NMDA receptors that, if 
maintained for a sufficient period of time, induces a massive influx of Ca2+ into the 
postsynaptic neuron which, in turn, triggers the activation of nNOS and overproduction 
of NO. In contrast, NO produced by activation of eNOS (Marks et al., 1996) and even 
NMDA receptors (Fergus & Lee, 1997), plays a protective role in brain ischemia by 
maintaining regional cerebral blood flow. (Esplugues, 2002) 
 Inhibition of nNOS with concentrations of NOS inhibitors that do not suppress 
eNOS activity reduces infarct volume, whereas the use of selective nNOS inhibitors is 
consistently neuroprotective in models of focal ischemia (Yoshida et al., 1994). 
Exacerbation of injury seems to occur through inhibition of eNOS with high doses of 
non-selective NOS inhibitors, which results in deleterious alterations of cerebral blood 
flow and a subsequent increase in infraction volume. (Esplugues, 2002) 
 
2.4.5.4  ROLE IN DISORDERS OF CNS 
 
 There is growing evidence to support a role for NO in the etiology of 
neurological conditions, including autoimmune and chronic neurodegenerative diseases. 
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 Diseases such as multiple sclerosis and Guillain-Barre syndrome, characterized 
by widespread loss of myelin, may see their neuronal symptoms exacerbated via the 
release of NO that accompanies the severe inflammation in the central and peripheral 
nervous system. (Esplugues, 2002) 
 In the spinal cord, nNOS expression precedes the death of motor neurones, 
which follows avulsion of spinal nerve roots (Wu et al., 1994), and pre-treatment with 
nNOS inhibitors substantially increases the number of surviving neurones (Wu & Li, 
1993). 
 The excessive release of both glutamate and NO, coupled with mitochondrial 
dysfunction and oxidative stress, has been implicated in a number of neurodegenerative 
diseases. This highlights a potential therapeutic role for specific NOS inhibitors in their 
pharmacological control (Hobbs et al., 1999).  
 For instance, nNOS is induced in various cortical regions following epileptic 
seizures (Huh et al., 2000). NOS neurones are spared in Alzheimer’s disease and NOS 
inhibitors provide neuroprotection against toxicity in primary cortical cultures (Hyman 
et al., 2000). Inhibition of nNOS markedly reduces the loss of dopamine neurones and 
clinical symptoms in a baboon model of Parkinson’s disease (Hantraye et al., 1996) and 
inhibition of NOS is protective in models of Huntington’s disease (Deckel, 2001). 
Significant changes in nNOS activity in the cerebrum and cerebellum follow the 
administration of metals such as aluminum and mercury, and suggest an involvement of 
this mediator in cerebral diseases induced by metals (Cucarella et al., 1998). 
 There are increased levels of NO production in viral and bacterial infections 
such as meningitis, and a role for NO has been clearly indicated in the disruption of the 
blood-brain barrier during inflammatory conditions (Brian et al., 1995). 
 NO has been implicated as a potential mediator of microglia-dependent primary 
demyelization, a hallmark of multiple sclerosis, and iNOS induction has been noted in 
the brains of patients with this autoimmune disease. NO may also be involved in the 
pathogenesis of sporadic amyotrophic lateral sclerosis and that of AIDS dementia (Bo et 
al., 1994).  
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2.4.6  NO IN THE PERIPHERAL NERVOUS SYSTEM 
 
 NO has a leading role as an inhibitory neurotransmitter of peripheral non-
adrenergic, non-cholinergic nerves. Peripheral nitrergic nerves have a widespread 
distribution, and are particularly important in that they produce relaxation of smooth 
muscle in the gastrointestinal, respiratory, vascular and urogenital systems. It is 
generally assumed that free NO is the transmitter substance released by nitrergic nerves. 
(Esplugues, 2002) 
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2.5  IMAGING TECHNIQUES OF NITRIC OXIDE 
 
 
2.5.1  CHEMILUMINESCENT REACTION INVOLVING OZONE 
 
 The concentration of NO can be determined using a simple chemiluminescent 
reaction involving ozone. A sample containing nitric oxide is mixed with a large 
quantity of ozone. The nitric oxide reacts with the ozone to produce oxygen and 
nitrogen dioxide. This reaction also produces light (chemiluminescence), which can be 
measured with a photodetector. 
NO + O3 → NO2 + O2 + light 
The amount of light produced is proportional to the amount of nitric oxide in the 
sample. (Fontijn et al., 1970) 
 
2.5.2  FLUORESCENT DYE 
 
 A group of fluorescent dye indicators which are also available in acetylated form 
for intracellular measurements exist. The most common compound is 4,5-
diaminofluorescein (DAF-2). (Nagano & Yoshimura, 2002)  
 Another one is represented by diaminoanthraquinone (DAA). A method for 
the direct measurement of intracellular NO production stimulated by penicillin G in 
cultured hippocampal neurons with this dye using laser scanning confocal microscopy 
was developed. Intracellular DAA fluorescence could specifically represent NO 
production based on two facts: (1) 3-morpholinosydnonimine, a NO donor, could dose-
dependently increase DAA fluorescence; and (2) haemoglobin, a NO scavenger, could 
inhibit the increase of DAA fluorescence. These results revealed that DAA could be 
used to indicate real-time and kinetic intracellular NO production of hippocampal 
neurons with higher sensitivity, specificity and accuracy. (Chen & Sheng & Zheng, 
2001) 
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 DAQ (1,2-diaminoanthraquinone) is the aromatic vicinal and has been already 
used to determine changes in NO production by imaging techniques. The dark violet 
DAQ possesses no direct fluorescence. NO reacts with the aromatic amino groups of 
DAQ at neutral pH and in the presence of oxygen. The final reaction product (ATD) 
shows fluorescence. (Schuchmann et al., 2002) 
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2.6  NEUROPLASTICITY 
 
 
 Neuronal activity can modify the behavior of neural circuits by one of three 
mechanisms: 
 by modifying the strength or efficacy of synaptic transmission at preexisting 
synapses, 
 by eliciting the growth of new synaptic connections or the pruning away of 
existing ones, 
 by modulating the excitability properties of individual neurons. (Malenka, 2002) 
 Neuroplasticity is the process of changing of neurons, the organization of their 
networks, and their function via new experiences. This idea was first proposed in 1890 
by William James. The evidence for neurogenesis is mainly restricted to the 
hippocampus and olfactory bulb, but current research has revealed that other parts of 
the brain, including the cerebellum, may be involved as well. (Wall & Xu & Wang, 
2002) 
 In the rest of the brain, neurons can die, but they cannot be created. However, 
there is now ample evidence for the active, experience-dependent reorganization of the 
synaptic networks of the brain involving multiple interrelated structures including the 
cerebral cortex. The specific details of how this process occurs at the molecular and 
ultrastructural levels are topics of active neuroscience research. 
 Neuroplasticity is an essential issue that supports the scientific basis for 
treatment of brain injury with goal-directed experiential therapeutic programs in the 
context of rehabilitation approaches to the functional results of the injury. 
 The subunit of neuroplasticity is the term synaptic plasticity which is the ability 
of the connection, or synapse, between two neurons to change in strength. It refers to 
the first of the mechanisms mentioned in the beginning of chapter. It is one of the 
important neurochemical foundations of learning and memory. 
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2.6.1  LONG - TERM POTENTIATION (LTP) 
 
 LTP is a long-lasting enhancement in signal transmission between two neurons 
that results from stimulating them synchronously (Cooke & Bliss, 2006). It is one of 
phenomena underlying the synaptic plasticity and it represents the ability of synapses to 
improve their connectivity in their strength. (Paradiso et al., 2007).  
 LTP is thought to be a synaptic correlate of learning and memory, and is most 
pronounced in higher brain centers involved in cognitive functions, particularly in the 
cerebral cortex and hippocampus. (Esplugues, 2002) 
 The forms of LTP differ in mechanisms depending on the regions of the brain 
when it occurs. For example in hippocampus, some of LTP types depend on NMDA 
receptors and others may depend on metabotropic glutamate receptors. NMDA 
receptor-dependent LTP exhibits specific properties including input specificity, 
associativity, cooperativity and persistence. The whole process in commonly divided 
into three phases: short-term potentiation, early LTP and late LTP. There is little known 
about the mechanisms of the first one but early LTP occurs when the concentration of 
Ca2+ inside the postsynaptic cell exceeds a critical threshold which can be evoked 
experimentally by applying a few trains of high-frequency stimuli; all processes realize 
through NMDA receptors (that is why called NMDA receptor-depend LTP) when 
activated by sufficient depolarization and bound by glutamate. Late LTP is induced by 
changes in gene expression and protein synthesis.      
 
2.6.2  LONG - TERM DEPRESSION (LTD) 
  
 LTD is an activity-dependent reduction in the efficacy of neuronal synapses 
lasting hours or longer (Massey & Bashir, 2007). It occurs in many areas of the CNS 
with varying mechanisms depending upon brain region and developmental progress. 
Cerebellum and hippocampus belong between the best characterized regions in this 
phenomenon. LTD is one of several processes that serve to selectively weaken specific 
synapses in order to make constructive use of synaptic strengthening caused by LTP. 
This is necessary because, if allowed to continue increasing in strength, synapses would 
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ultimately reach a ceiling level of efficiency, which would inhibit the encoding of new 
information (Purves et al., 2008). 
 Physiological principle of LTD in hippocampus is based on controlling of influx 
of postsynaptic Ca2+ through NMDA receptors because the process of depression 
depends on the timing and frequency of Ca2+ influx and it occurs only in small and slow 
rises of postsynaptic Ca2+ levels between Schaffer collaterals and CA1 pyramidal cells. 
Experimentally, it is elicited by repetitive stimulation for extended time periods at a low 
frequency. 
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2.7  EPILEPSY 
 
 
2.7.1  DEFINITION 
 
 Epilepsy is a common chronic neurological disorder characterized by recurrent 
unprovoked seizures. These seizures are transient signs and/or symptoms of abnormal, 
excessive or synchronous neuronal activity in the brain.  
 About 50 million people worldwide have epilepsy, with almost 90% of these 
people being in developing countries. Epilepsy is more likely to occur in young children 
or people over the age of 65 years; however it can occur at any time. 
 Not all epilepsy syndromes are life long - some forms are confined to particular 
stages of childhood. Epilepsy should not be understood as a single disorder, but rather 
as syndromic with vastly divergent symptoms but all involving episodic abnormal 
electrical activity in the brain. (Fischer et al., 2005) 
 
2.7.2  PATHOPHYSIOLOGY 
 
2.7.2.1  PATHOPHYSIOLOGY IN POPULATION  
 
 Changes that occur during epileptogenesis are poorly understood but are thought 
to include cell death, axonal sprouting, reorganization of neural networks, alterations in 
the release of neurotransmitters, neurogenesis. These changes cause to the neurons to 
become hyperexcitable and can lead to spontaneous seizures. (Herman, 2006) 
 Brain regions that are highly sensitive to insults and can cause epileptogenesis 
including temporal lobe structures such as the hippocampus, the amygdala and the 
piriform cortex. (Aroniadou-Anderjaska, 2008) 
Gene mutations 
 Gene mutations have been linked to some types of epilepsy. Several genes that 
code for protein subunits of voltage-gated and ligand-gated ion channels have been 
 46
associated with forms of generalized epilepsy and infantile seizure syndromes. Several 
ligand-gated ion channels have been linked to some types of frontal and generalized 
epilepsies. One speculated mechanism for some forms of inherited epilepsy are 
mutations of the genes which code for sodium channel proteins; these defective sodium 
channels stay open for too long thus making the neuron hyper-excitable. Glutamate, an 
excitatory neurotransmitter, may thereby be released from these neurons in large 
amounts, which by binding with nearby glutamanergic neurons, triggers excessive 
calcium (Ca2+) release in these post-synaptic cells. Such excessive calcium release can 
be neurotoxic to the affected cell. The hippocampus, which contains a large volume of 
just such glutamanergic neurons (and NMDA receptors, which are permeable to Ca2+ 
entry after binding of both sodium and glutamate), is especially vulnerable to epileptic 
seizure, subsequent spread of excitation, and possible neuronal death. Another possible 
mechanism involves mutations leading to ineffective GABA (the brain's most common 
inhibitory neurotransmitter) action that results break-down of inhibitory mechanisms in 
CNS and induces uncontrolled excitation in neurons. Epilepsy-related mutations in 
some non-ion channel genes have also been identified. (Hopkins et al., 1995)  
Chemical agents 
 Imbalance of intrinsic chemical compounds, natural or artificial, can activate 
cascade of processes that can finally lead to seizure activity. These substances are called 
neurotoxins and their exposure occurs for example in chemotherapy, radiation 
treatment, drug therapies, but as well as in exposure of heavy metals, certain food, 
industrial or cleaning solvents, cosmetics, etc.  Repeated exposures to some pesticides 
have been shown to induce seizures in both humans and animals. One mechanism, 
proposed for this, is called excitotoxicity. (Hopkins et al., 1995) 
Traumatic brain injuries 
 Seizures may also occur after traumatic brain injury; these are known as post-
traumatic seizures (PTS). In the period between a brain injury and onset of epilepsy, 
brain cells may form new synapses and axons, undergo apoptosis or necrosis, and 
experience altered gene expression. In addition, damage to particularly vulnerable areas 
of the cortex such as the hippocampus may give rise to post-traumatic epilepsy (PTE). 
In other cause, blood that gathers in the brain after an injury may damage brain tissue 
 47
and thereby cause epilepsy; or the products that result from the breakdown of 
hemoglobin from blood may be toxic to brain tissue. The “iron hypothesis” holds that 
PTE is due to damage by oxygen free radicals. 
 Abnormalities in the release of neurotransmitters may play a role in the 
development of PTE. Traumatic brain injury can lead to the excessive release of 
glutamate and other excitatory neurotransmitters and it leads to excitotoxicity, damage 
to brain cells through overactivation of the biochemical receptors that bind and respond 
to excitatory neurotransmitters. This overactivation of glutamate receptors damages 
neurons. 
 Important independent risk factors for PTE include acute intracerebral 
hematoma (especially subdural hematoma), brain contusion, increased injury severity 
(as reflected by loss of consciousness or posttraumatic amnesia lasting  more than 24 h), 
occurrence of early posttraumatic seizures, and being older than 65 years at the time of 
injury. (D`Ambrosio & Perucca, 2004) 
 
2.7.2.2  PATHOPHYSIOLOGY IN EXPERIMENTAL ANIMAL MODELS 
 
 Because of ethical codex, the scientists cannot measure all recordings from 
neurons of living human brain. But properly controlled experiments can be successfully 
done with animal models of epilepsies.  
In vivo 
 In vivo (Latin for “within the living”) is experimentation using a whole, living 
organism. In vivo imaging provides a noninvasive method for imaging biological 
processes in live animals in order to understand metabolic processes, effects of drugs or 
disease progression. Animal models can be studied either acutely (in which the animal 
is sacrificed at the end of experiment) or chronically (where the same animal can be 
studied repeatedly over long periods). It is useful mostly for long-term experiments in 
one animal and long-term collection of data in the same conditions because it is still the 
same organism which progresses in time. 
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 Models of epilepsy can be induced by application of convulsant substances to 
brain of animals. All these convulsant substances are acting through ionic channels or 
transmitters or metals. Metals such as aluminum, iron or cobalt produce these focal 
models (Hopkins et al., 1995); or the neurotoxin kainic acid appears to have a 
preferential excitable effect on hippocampus when injected systematically (Nadler, 
1981). Other options are in using the chemicals such as Bicuculline (see Chapter 
2.7.4.7), Carbachol (see Chapter 2.7.4.8), 4-aminopyridine (see Chapter 2.4.7.9), etc. in 
the same way like in vitro studies. In general, we can say that models used in vitro are 
suitable for in vivo studies too and in additional, in vitro experience should prepare good 
conditions and adequate results in measurement for following in vivo studies.     
 Or the seizure activity can be elicited by electrode stimulation. The kindling 
model represents this option in research. It is a widely used model for the development 
of seizures and epilepsy. The word kindling is a metaphor: the increase in response to 
small stimuli is similar to the way small burning twigs can produce a large fire. It means 
that duration and behavioral involvement of induced seizures increases because seizures 
are induced repeatedly. In this model a stimulating electrode is put in excitable brain 
tissue, most commonly the amygdala, and brief shocks are given on a daily basis. After 
few days or weeks it progresses to full epileptiform discharges and behavioral 
consequences (Purpura et al., 1978). 
In vitro 
 Physiological experiments are difficult in living whole brain tissue in terms of 
low accessibility, lack of control of the neuronal micro-environment, confounding 
effects of anesthetics and mechanical instability from cardiorespiratory pulsations. 
Experiments performed in vitro minimize these difficulties at the cost of isolation of 
brain tissue from its usual communicating structures. 
 In vitro (Latin for “within the glass”) experiment is performed not in a living 
organism but in a controlled environment. In vitro electrophysiological investigation 
can be carried out on normal tissue that is made epileptic “in the dish” or on tissue 
removed from animal models of chronic epilepsy. Preparations can be acute (slices, 
dissociated cells, etc.) or long-term (e.g. tissue cultures (Pitkänen et al., 2006). The most 
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useful of the in vitro techniques for the study of epilepsy has been the explanted 
hippocampal slice (Hopkins et al., 1995).  
 Transverse slicing of the hippocampus preserves its laminar circuitry which is 
very useful for these experiments. Addition of chemicals to the media allows control of 
the microenvironment, and intracellular recordings are relatively easy to obtain. We can 
evoke bursting which is taken as a model of epileptiform activity by electrode 
stimulation, addition of pharmaceuticals or changing intracellular and extracellular 
conditions of neurons (for more details see 2.7.3.2, 2.7.4 or Methods).  
 
2.7.3  ACUTE SLICES 
 
 Animal models of epilepsy are mostly used to investigate fundamental neuronal 
mechanisms of both abnormal (usually epilepsy related) and normal brain function. 
Animal models are also important, however, for research designed specifically to devise 
new diagnostic approaches or to test the efficacy of new antiepileptic drugs or other 
novel therapeutic interventions. Animal models are essential for understanding basic 
mechanisms of epilepsy (structural and functional abnormalities), investigation of 
pharmacotherapy and alternative therapies and developing a prevention of epilepsy, 
antiepileptogenesis, because none of current antiepileptic drug is known to be 
antiepileptogenic.  
 The most popular in vitro preparations are acute brain slices, consisting of 200- 
to 600-μm thin sections of living brain tissue, which can be obtained from any species 
with a complex brain. 
 
2.7.3.1  POTENTIAL PROBLEMS 
 
 Some compoundable problems must be taken into account by investigators using 
slice preparations: 
 Inevitably such preparations have undergone a period of ischemia. Further, 
many fiber projections entering and leaving the brain slice are severed.  
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 Moreover the thickness of the preparation requires a nutrition supply that is 
dependent on exchange by diffusion from the artificial cerebrospinal fluid 
(ACSF) and diffusion processes are much less efficient than in real conditions. 
 As a result of the acute lesion, and in analogy to in vitro observations after acute 
transaction of the spinal cord, there is a drastic reduction of spontaneous 
synaptic activity. 
 The last point is less important where physiological synaptic activity can be 
maintained by intraslice circuitry (e.g. in hippocampal formation) and sufficient oxygen 
and glucose supply is well-balanced by saturation with 95% oxygen and high glucose 
content. (Pitkänen et al., 2006) 
 
2.7.3.2  PREPARATION, MAINTENANCE AND RECORDING 
 
 Most laboratories used a tissue chopper for cutting the tissue into thin slices but 
later, vibratomes were adopted in many laboratories because they appear to make slices 
with less mechanical damage. The slices are maintained in the static bath of gassed 
ACSF, placed on the lens paper, which facilitates transfer to the recording chamber. 
Another important issue of experiment is the temperature at which is the tissue 
maintained because SLE is difficult to induce at temperatures below 33°C. And another 
one is the composition of the ACSF (see Methods for more details). The osmolarity of 
the solution should be about 290mOsm and Ca2+, Mg2+ and K+ concentrations must be 
carefully adjusted because even small variations in concentration of these ions have 
marked effects on neuronal activity. (Pitkänen et al., 2006)  
 Slice recordings can be performed in an interface chamber or in a submerged 
chamber. First, an interface chamber is characterized by presentation of two 
environments in the chamber when the slice placed on the bearing plate overflows by 
ACSF on a lower side and on the upper is surrounded by atmosphere of humidified gas. 
Second, a submerged chamber isolates a slice from atmosphere conditions by 
submerging in ACSF and the solution overflows the slice in both sides, above and 
below. Maintaining in submerged chamber has proven much harder because there is a 
possibility of problem with diffusion of oxygen and interference sounds in recording 
developed by flow of ACSF. But, if successful, would offer important experimental 
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advantages over interface conditions, including faster exchange of pharmacological 
agents, visually guided patch-clamp recordings (recordings used for measurement of 
membrane current at single ion channel or multiple channel at once) and advanced 
imaging techniques. (Hájos et al., 2009) 
 Submerged chamber design is modified in two ways. First, in order to reduce the 
volume of the chamber and direct the superfusion fluid over slice, an inert plastic insert 
is used. The second modification allows a double superfusion system to be used. In this 
design, the slice is placed on a mesh glued between two plastic rings. Two separate fluid 
inlets allow ACSF to flow separately above and below the slice. (Hájos et al., 2009) 
In the recording chamber, we have different possibilities to use pharmacological 
agents to influence function of the nervous tissue. We can incubate the slice in the 
recovery chamber or add substances into the perfusion during recording.  
As mentioned above, the most useful model in vitro for investigation in epilepsy 
research seems to be a hippocampal transverse slice of rat because of its unidirectional 
connectivity and similarity to the human structure and function. 
 
2.7.4  EXPERIMENTAL MODELS 
 
 The mechanisms, which induce an epileptiform activity on hippocampal slices in 
vitro experiments, make use of ionic changes in extracellular conditions (by lowering or 
increasing the concentration of specific ions in ACSF), addition of pharmaceuticals into 
the ACSF, stimulating the slice by microelectrode, or combination of all mentioned 
methods. The success in inducing an activity depends mostly on accurate concentration 
of ACSF and particularly on setup of each laboratory. 
 
2.7.4.1  GABAergic DISINHIBITION 
 
 In the absence of GABAergic neurotransmission, synchronized inter-ictal-like 
(inter-ictal means period of time between seizures) burst can occur. These bursts depend 
on fast glutamatergic neurotransmission to activate AMPA and NMDA receptors. In 
general, the activation of ictal-like (ictal means a period of time during an actual 
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seizure) events in vitro requires additional pharmacologic manipulation, such as 
elevation K+ (see Chapter 2.7.4.6) or addition of Bicuculline (see Chapter 2.7.4.7), 
competitive antagonist of GABAA receptors (see Chapter 2.3.3). (Pitkänen et al., 2006) 
 
2.7.4.2  KAINIC ACID 
 
 Kainic acid (KA) is a specific agonist for the kainate receptor used as an 
ionotropic glutamate receptor which mimics the effect of glutamate and has presynaptic 
and postsynaptic effects. KA can directly depolarize neurons that express KA receptors, 
such as CA3 pyramidal cells and interneurons, leading them to generate action 
potentials. Despite its epileptogenicity in vivo, it has not been extensively used to study 
the intention and propagation of seizure-like discharges in the hippocampal slice 
preparation. (Pitkänen et al., 2006) 
 
2.7.4.3  BLOCK OF K+ CHANNELS 
 
 Blocking K+ channels  with 4-Aminopyridine (see Chapter 2.7.4.9), an organic 
compound, its molecule is one of the three isomeric amines of pyridine; it is a relatively 
selective blocker of voltage-activated K+ channels; it prolongs action potentials) induces 
interictal-like and ictal-like discharges in hippocampus. (Pitkänen et al., 2006) 
 
2.7.4.4  LOW-Ca2+ MODEL 
 
 Lowering Ca2+ abolishes neurotransmission and results in spontaneous 
paroxysmal discharges. These events arise focally and spread through CA1 region. This 
model may be particularly valuable for the study of synchronization mechanisms and 
for investigating interventions to abort or stop these discharges. (Pitkänen et al., 2006) 
  
 
 In our research, there is a tendency for investigation of five models of 
epileptiform activities to demonstrate a role of NO, respectively to demonstrate and 
induce SLEs in vitro in our setup in submerged chamber which is required for imaging 
techniques and NO detection…..low-Mg2+ (magnesium), high-K+ (potassium), 
Bicuculline, Carbachol and 4-Aminopyridine model. Performance of the models was 
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done on hippocampal slices (see Methods for more details). There is a list of 
experiments made in each model for purpose of confrontation with previous researches.  
 
2.7.4.5  LOW-Mg2+ MODEL 
 
 Low-Mg2+-induced epileptiform activity results from increased synaptic 
excitation due to facilitated activation of NMDA receptors (Mody et al., 1987). NO 
decisively modulates low-Mg2+- induced epileptiform activity. The induction of low-
Mg2+ epileptiform activity is associated with an increase in NO production. The 
maintenance of low-Mg2+-induced epileptiform activity requires an increased level of 
NO concentration: reduction of NO level can block activity, whereas elevation of NO 
levels can induce activity. (Schuchmann, 2002) 
 The studies show increasing NO production following removal of Mg2+ ions 
from the perfusion medium before the first seizure-like events (SLEs) arise. Reducing 
the endogenous NO production using the NOS inhibitor L-NAME suppressed SLEs and 
therefore underlines the meaning of NO for low-Mg2+-induced epileptiform activity. 
Furthermore, suppressed epileptiform activity due to blocked endogenous NO 
production was reactivated by exogenously applied NO. Finally, the required 
endogenous or exogenous amounts of NO for the induction of low- Mg2+-induced 
epileptiform activity were found to be approximately equal. (Schuchmann, 2002) 
 It is suggested that the NMDA/NOS system is of primary importance in a variety 
of physiological and pathological processes of the brain (Contestabile, 2000). Lowering 
the extracellular Mg2+ concentration has been shown to induce spontaneous epileptiform 
activity by removal of the voltage-dependent Mg2+ block from the NMDA receptor 
(Mody et al., 1987). 
 Enhanced NO production during low-Mg2+- induced epileptiform activity may 
influence the decrease in neuronal energy supply and may accelerate the transition into 
the resistant late activity. The finding of an increased frequency of SLEs after elevation 
of NO concentration corresponds well with hypotheses that attribute the transition to 
late activity in the low-Mg2+ model to an energetic failure (Schuchmann, 2002). 
Furthermore, mitochondria have been demonstrated to possess an autonomous system to 
generate NO, localized in the inner mitochondrial membrane, which may take part in 
 54
the control of ATP production (Giulivi et al., 1998). There is a suspect of functional role 
for mitochondria in epileptiform activity via neuronal energy metabolism, which may 
be modulated by this mitochondrial NO synthesis. (Schuchmann, 2002)  
 Schuchmann et al., 2002, measured the production of NO during low-Mg2+- 
induced epileptiform activity in rat hippocampal-entorhinal cortex slices in submerged 
chamber. They induced spontaneous SLEs which developed during prolonged washout 
of Mg2+ ions from ACSF (zero Mg2+ model). In 7 of 7 brain slices spontaneous series of 
SLEs was recorded. The frequency of low-Mg2+-induced SLEs was 0.53 ± 0.19 min-1 
and their duration was 22 ± 1.8 s. 
 Low-Mg2+ model results a long-term activation of NMDA receptors so that is far 
away from reality of epileptic activity in vivo, that is why we decided to not use this 
model for following researches. 
 
2.7.4.6  HIGH-K+ MODEL 
 
 Because K+ currents play an essential role in controlling neuronal excitability, it 
was initially hypothesized that elevations of extracellular K+ are the cause of 
epileptiform activity. According to the potassium accumulation hypothesis, extracellular 
K+ fluctuates around a stable baseline during physiological activity levels. A transient 
increase triggers the occurrence of a seizure during which K+ further accumulates. As a 
result, neurons become even more depolarized, fire more APs, and release even more 
K+ into the extracellular space. Eventually, these run-away dynamics (positive 
feedback) come to an end when the neurons are so depolarized that they can no longer 
spike due to sodium channel inactivation. At this point, the seizure terminates. (Fröhlich 
et al., 2008) 
   In addition, this model relates with the Leão`s phenomenon call spreading 
depression (SD) which can be set off by high K+ levels in extracellular space. This 
phenomenon is characterized by rapid and nearly complete depolarization of a sizable 
population of brain cells with massive redistribution of ions between intracellular and 
extracellular compartments and propagates slowly as a wave in brain tissue. SD can be 
produced by positive feedback achieved by increase of extracellular K+ concentration 
that activates persistent inward currents which then activate K+ channels and release 
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more K+. (Somjen, 2001) These levels of extracellular K+ are so high (up to 100mM!) 
that they lead into the depression of neuronal activity; normally it is about 3 mM and 
during evoked SLE there is concentration up to 10mM of K+.  
 Increasing in [K+] 0 also directly affect synaptic inhibition. The equilibrium 
potential of GABAA receptors shifts toward less negative values in elevated [K+]o. 
(Fröhlich et al., 2008) 
 This model is particularly useful because it causes an elevation of the general 
excitability of all neuronal networks (Pitkänen et al., 2006). 
 Fröhlich et al., 2008, described in their work that elevation of K+ concentration 
in the ACSF to 7.5 or 8.5mM was sufficient to trigger both periodic network activation 
(“interictal spikes”) and in some cases events resembling electrographic seizures with a 
“tonic” firing and “clonic” bursting phase in the hippocampus. Furthermore, SLEs 
occurred depending on the degree of [K+]o increase evoked by extracellular electrical 
stimulation or focal potassium injection in a high- K+ and low-Ca2+ model. Together, 
these ionic models illustrate that elevated [K+]o is clearly sufficient to trigger 
synchronized oscillatory activity at various frequencies in the hippocampal networks in 
vitro. 
 Leschinger et al., 1993, studied some of the physiological and pharmacological 
properties of an in vitro model of epileptic seizures induced by elevation of [K+]o (to 
8mM and 10mM) in combination with lowering of [Mg2+]o (to 1.4mM and 1.6mM) and 
[Ca2+]o (to 0.7mM and 1mM) in rat hippocampal slices. The resulting data suggest that 
the high-K+ model of epileptiform activity is a good model of focal convulsant activity. 
 Sagratella et al., 1987, made a result in their research that increase of the 
potassium concentration up to 8mM in the superfused solution of rat hippocampal slices 
leads to the development of an epileptiform bursting. They made several other 
measurements with antagonist L-PIA and its ability to block the potassium induced 
epileptiform activity. 
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2.7.4.7  BICUCULLINE 
 
 Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. 
Since it blocks the inhibitory action of GABA receptors, the action of Bicuculline 
mimics epilepsy.  
 This property is utilised in laboratories across the world in the in vitro study of 
epilepsy, generally in hippocampal or cortical neurons in prepared brain slices from 
rodents. This compound is also routinely used to isolate glutamatergic (excitatory amino 
acid) receptor function. 
 The action of Bicuculline is primarily on the ionotropic GABAA receptors, 
which are ligand-gated ion channels concerned chiefly with the passing of chloride ion 
across the cell membrane, thus promoting an inhibitory influence on the target neuron. 
These receptors are the major targets for benzodiazepines and related anxiolytic drugs.  
 In addition to being a potent GABAA receptor antagonist, bicuculline can be 
used to block Ca2+-activated potassium channels. (Khawaled et al., 1999) 
 More recently, blockage of K+ channels and prolongation of Ca2+ action 
potentials has been also suggested as a possible mechanism of seizure induction by 
Bicuculline (Engel & Pedley, 2008).  
 Desalvo et al., 1995, studied BOLD fMRI changes in aneshetized Wistar rats 
during bicuculline-induced tonic-clonic seizures. Bicuculine was injected systematically 
and seizure activity was observed on EEG. In the work of Wu et al., 1994, Bicuculline 
led to a marked increase in the spontaneous discharged rates of 6/7 (85.71%) neurons in 
an epileptiform pattern. 
 
2.7.4.8  CARBACHOL 
 
 Carbachol is a drug that binds and activates the acetylcholine receptor. Thus it is 
classified as a cholinergic agonist. Furthermore, Carbachol is a parasympathomimetic 
(mimicking the parasympathetic nervous system) that stimulates both muscarinic and 
nicotinic receptors and mimics epilepsy in this process.  
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 Cruickshank et al., 1994, made several experiments to determine the types of 
acetylcholine receptors involved in the initiation of epileptic seizures from the zona 
incerta, in subthalamus, and surrounding structures by cholinergic stimulation in rats. 
Unilateral intracerebral microinjection of the mixed muscarinic and nicotinic agonist 
carbachol produced generalized seizures in 12 of 20 rats studied. (Cruickshank et al., 
1994). The same result achieved Peterson and Armstrong, 1999, in their intention to 
determine the role of cholinergic mechanism by the microinjection of Carbachol into 
the nucleus reticularis pontis oralis. Bawin et al., 1994, investigated the role of nitric 
oxide in controlling the rate of occurrence of muscarinic rhythmic slow activity 
episodes induced by Carbachol in rat hippocampal slices. 
 
2.7.4.9  4-AMINOPYRIDINE 
 
 4-Aminopyridine (4-AP) is an organic compound and its molecule is one of the 
three isomeric amines of pyridine. The largest scale industrial application of 4-
aminopyridine is as a precursor to the drug Pinacidil, which affects potassium ion 
channels. It is an extremely poisonous bird poison and it is highly poisonous to 
mammals too. 
 4-Aminopyridine (4-AP) is a voltage-gated, fast potassium channel blocker 
capable of improving axonal conduction by facilitating the propagation of APs in 
demyelinated nerve fibers. It does not replace damaged myelin but users of 4-AP report 
dramatic improvement in a number of symptoms especially paraesthesia. It has been 
used clinically in Lambert-Eaton syndrome and multiple sclerosis (MS). It has been 
shown to improve visual function and motor skills and relieve fatigue in patients with 
MS. 
 It is used primarily as a research tool, in the laboratory; 4-AP is a useful 
pharmacological tool in studying various potassium conductances in physiology and 
biophysics. It is a relatively selective blocker of members of voltage-gated K+ channels. 
Some reports have shown that overdoses with 4-AP can lead to paraesthesia, seizures, 
and atrial fibrillation. For the purpose of our study is the most essential that it cases 
seizures. 
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 Schuchmann et al., 1999, induced an epileptiform activity in brain slices of 
Wistar rats and made it in two experimental models, low-Mg2+ and addition 250μM 4-
AP, for the purpose of their experiment in relative energy failure in entorhinal cortex 
during these SLEs. After exposure to 250μM 4-AP, SLEs were observed at a frequency 
of 0,32 ± 0,1min-1; the duration was 19 ± 1.5 s. Late recurrent discharges were not 
observed in 9 out of 9 slices after a maximal exposure time of >3h. 
 
2.7.5  ELECTROPHYSIOLOGY 
 
 In a seizure focus, every single neuron has the paroxysmal depolarization shift 
(PDS), which is a stereotypic and synchronized electrical response. Activation of 
excitatory glutamate-mediated channels such as AMPA and NMDA receptor channels 
as well as voltage-gated Ca2+ primarily cause the depolarizing phase. The PDS consists 
of a sudden, large 20 - 40mV, long-lasting (50 - 200ms) depolarization, which triggers a 
train of action potentials at the peak of the PDS. The afterhyperpolarization appears 
after PDS. 
 Voltage-gated K+, Na+, Ca2+ channels and the others intrinsic membrane 
properties of the neuron as well as synaptic inputs from excitatory (glutamatergic) and 
inhibitory (GABAergic) neurons respectively shape the PDS and the 
afterhyperpolarization. 
 A typical cortical pyramidal neuron responds to excitatory input in an excitatory 
postsynaptic potential (EPSP) followed by an inhibitory postsynaptic potential (IPSP). 
The PDS can be thus viewed as a gross exaggeration of the normal depolarizing and 
hyperpolarizing components observed in neurons in a typical cortical circuit. 
 Hippocampal neurons in the CA3 region exhibit PDS behavior under normal 
conditions and that is the way how they differ from most neurons. PDS is ended by the 
afterhyperpolarization. The generators of the afterhyperpolarization are primarily 
calcium- and voltage-dependent K+ channels as well as GABA-mediated chloride and 
K+ conductance.  The Ca2+ entry through voltage-dependent Ca2+ channels and NMDA 
channels triggers calcium-dependent, particularly voltage-dependent Ca2+. The synaptic 
activity drives the sequences of depolarization and hyperpolarization that is why many 
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convulsants act by either enhancing excitatory or blocking inhibition which can be used 
in pharmacological treatment of epilepsy. The effective anticonvulsants are drugs that 
block excitation of enhance inhibition. 
 As a result of exitotoxic lesion of hippocampal sclerosis is the most common 
pathologic finding in TLE. Hippocampal sclerosis involves hippocampal cell loss in the 
CA1 and CA3 regions and the dentate hillus.  
 The break down of surround inhibition is the mechanism of seizure, but we still 
don’t know what causes a seizure to occur at any particular moment. There are many 
clinical factors such as stress and sleep derivation triggering seizures to in some 
patients, thus it is possible that diffuse cortical cholinergic, noradrenergic or 
serotonergic projections may play a crucial modulatory roles in some cases. Sensory 
stimuli such as flashing lights can also trigger seizures and we suggest that repeated 
excitation of circuits a frequency dependent manner providing another possible cellular 
mechanism for changing network excitability. (Konopková,  2004) 
 
2.7.6  THE ROLE OF NITRIC OXIDE 
 
 The functional involvement of NO in epileptiform activity has been 
demonstrated by several researchers. However, the role of NO in the expression of 
epileptiform activity is still unclear. NO has been proposed as an endogenous 
proconsulvant (Yasuda et al., 2001) as well as an anticonsulvant (Ferraro et al., 1997). 
 In the present studies, there is a tendency to investigate the role of NMDA/NOS 
system on epileptiform activity in the entorhinal cortex. The functional role of NO in 
epilepsy is controversial (Schuchmann, 2002). On the one hand, NO is known to 
activate guanylate cyclase, which increases cGMP levels and finally may cause an 
elevation in presynaptic release of glutamate (Garthwaite, 1991). Furthermore, increase 
in NO by the application of the NOS activator L-arginine has been shown to potentiate 
NMDA-induced seizure activity in the prepiriform cortex (De Sarro et al., 1993). On the 
other hand, NO has been suggested to cause a negative feedback on NMDA receptors 
by alteration of the receptor redox modulatory site (Lipton et al., 1993) and via 
blockage of the NMDA recognition site of the receptor (Manzoni et al., 1992). 
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 Several studies have suggested that some of the physiological and 
pathophysiological NO effects reveal a NO-modifying action on mitochondrial 
function. NO has been demonstrated to disturb intracellular Ca2+ homeostasis and 
mitochondria functions (Doutheil et al., 2000). Moreover, it has been demonstrated that 
NO causes a Ca2+/calmodulin-dependent synaptic potentiation in hippocampal CA1 
neurons, which could be blocked by L-NAME, NOS inhibitor (Ko & Kelly, 1999). In 
addition, there may be a synergic role for intracellular Ca2+ and NO in causing 
mitochondrial dysfunction (Keelan et al., 1999). Furthermore, increased NO 
concentration has been shown to inhibit mitochondrial functions and neuronal energy 
metabolism (Brorson et al., 1999). 
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2.8  EPILEPSY AND REHABILITATION 
 
 Epilepsy should not be understood as a single disorder, but rather as syndromic 
with vastly divergent symptoms but all involving episodic abnormal electrical activity 
in the brain. Rehabilitation in epilepsy includes all aspects of daily living such as 
medical treatment; social care, mainly a person’s ability to cope in society; 
psychological intervention like a depression and stress; and neuropsychological aspects 
like memory difficulties or cognitive problems.  
 
Using of physical rehabilitation in epilepsy is less frequent than in other 
neurological disorders. Or have you ever heard about physical rehabilitation in 
epilepsy? There is a little mention about this in literature, rather less than more. But the 
epilepsy is a neurological disorder like another one so it deserves little more attention of 
physiotherapy. A minority of individuals, however, may have physical disabilities, the 
most common being hemiparesis and ataxia, for which assessment and intervention by a 
physiotherapist form an important part of rehabilitation process. Moreover, 
physiotherapy can be taken in account in process of prevention of frequency in 
epileptiform seizures. Physical activities of the patients with epilepsy play an important 
role in releasing of stress and depression and support a solid healthy life style as the 
most important part of prevention. In addition, physiotherapy should prevent the side 
effects of drugs using in epilepsy (antiepileptics; anticonvulsants) such as putting on 
weight, ataxia, vertigo, headache, nystagmus, paraestheazia, problems in cognitive 
functions (dysarthria), etc. Then the therapeutical procedures should be aimed on weight 
reduction by therapeutical physical training; and supervision of movement which can be 
achieved by sensomotoric stimulation, proprioceptive neuromuscular stimulation, 
balance training and other methods used in daily routine. Problems in cognitive function 
can be dissolved for example by stimulation or soft massages in oral facial region or 
Sister Kenny Method, all with cooperation of speech therapist. 
 
Moreover, epilepsy is the most common chronic disorder of the CNS and we 
know that it performs as a symptom of many other neurological disorders. For example 
cerebral palsy, in numbers, seizures occur in about half of those with this disorder and 
are much more common in tetraplegic (94%) and hemiplegic cerebral palsy (34%) than 
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in extrapyramidal form, although epilepsy is also common in the mixed forms. Epilepsy 
is related to structural damage, for example in congenital hemiparesis it occurs in half of 
those with cortical/subcortical atrophy, less commonly in those with unilateral 
ventricular dilatation. Epilepsy also occurs in about a quarter of those with 
meningomyelocele and hydrocephalus and there is also evidence that after head injury 
or intracranial surgery some patients can be identified to have a substantial risk of 
developing epilepsy. (Hopkins et al., 1995) 
 
 So, as you can see, it is a large amount of patients with specific diagnosis whom 
the physiotherapist meets in his routine, both in the hospital and private practice and at 
least, he should be prepared to afford them an adequate first aid. All of these arguments 
make the physiotherapy in epilepsy an essential part of global approach of 
rehabilitation. 
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3.  AIMS AND HYPOTHESIS 
 
 
3.1  AIMS 
 
 The aim of our experiment is to evoke an epileptic activity in rat hippocampal 
slices in vitro in our setup which is required for imaging techniques and NO detection in 
following researches and determination a role of NO in disorders of nervous system. 
We want to evoke this activity in following five experimental models: low-Mg2+, high-
K+, Carbachol, Bicuculline and 4-AP model. 
 
3.2  HYPOTHESIS 
 
 We assume that epileptic activity will be evoked in all experimental models 
(low-Mg2+, high-K+, Carbachol, Bicuculline and 4-AP) in our setup because of previous 
success of other investigators in these models mentioned in their reviews and because of 
well-prepared laboratory equipment.    
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4.  METHODS 
 
 
4.1  CHARACTERIZATION OF THE GROUP OF ANIMALS 
 
 Experiments were performed on slices prepared from adult male Wistar albino 
rats (100-180g). Rats were housed in a controlled environment (temperature 22 ± 1 °C, 
humidity 50-60%, lights on 06:00-18:00 h) with free access to food and water. 
Experiments were approved by the Animal Care and Use Committee of the Institute of 
Physiology of the Academy of Sciences of the Czech Republic. Animal care and 
experimental procedures were conducted in accordance with the guidelines of the 
European Community Council directives 86/609/EEC. 
 
4.2  SLICE PREPARATION AND MAINTENANCE  
 
 For the purpose of this study we have used live rat brain tissue slices. Rats were 
deeply anaesthetized with ether and decapitated. Brain was rapidly removed from the 
scull, cut in oxygenated (95%) and cooled (-0, 5 °C) artificial cerebrospinal fluid 
(ACSF) using vibratome in coronal slices of 400µm of thickness. The slices contained 
both, the somatosensory cortex and the hippocampus, were transferred immediately 
after the preparation to a holding chamber filled with ACSF and oxygenated; they were 
placed on the chamber bottom on a lens paper for easier later manipulation. After 120 
minutes recovery they were submerged into recording chamber through which 
oxygenated ACSF was perfused (5 ml/min) using a peristaltic pump (Minipuls 3 - 
GILSON) and perfused in stable temperature ± 36 °C. The temperature was maintained 
by Temperature Controller (SuperTech). The composition of the perfusion solution was 
(in mM): 126 NaCl; 26 NaHCO3; 1.8 KCl; 1.25 KH2PO4; 1.3 MgSO4; 2.4 CaCl2; 10 
glucose.  
The recordings were made in the submerged recording chamber. Slice was fixed 
in the chamber on the mesh glued and the ACSF was perfused in mentioned speed 
above and below the slice and then drained away. Stimulating and detection electrode 
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were fixed as mentioned below with the eye-control in microscope and microscope 
imaging on PC with cooled 12-bit CCD-camera (RETIGA2000R). 
 
4.3  ELECTROPHYSIOLOGICAL SYNAPTIC ACTIVATION 
 
Synaptic activation of the tissue was made with bipolar stimulating electrode 
placed in hillus of the dentate gyrus of hippocampus (Mossy fibers). The stimulating 
electrode is made from double-chamber glass tube with double silver wire inside. For 
field potentials recording extracellular glass microelectrodes (8-10 M Ω) filled with 4M 
NaCl was used and placed in pyramidal layer of CA1 region (Fig. 2.3). The detection 
electrode is made from glass tube (theta tube) filled with NaCl fluid (as mentioned 
above) and chromed silver wire. 10 minutes after the replacement of the slice into the 
recording chamber, single shock stimulation with supramaximal stimulus was applied 
and field responses were recorded. The very first stimulation was done for 
determination of the functionality of stimulating electrode, to find the place in the tissue 
suitable for recordings and for the functionality of the whole slice.   
 
 Stimulation was made according to stimulation protocol by paired pulse (p) at 
125 ms with isolated pulse stimulator (MODEL 2100, A-M Systems). We stimulated 
the tissue every 5 minutes. 
 For the purpose of our study we changed a concentration of perfused ACSF. In 
every model we changed a concentration of ACSF depending on the characteristics of 
model which we wanted to evoke. At first, every slice was washed out with regular 
ACSF and then changed for that one with changed concentration. It must be oxygenated 
at least 5 min in advance before perfused and stored in the stable temperature. In the 
case of models based on extracellular ionic changes we decreased or increased ionic 
concentration in ACSF. And in the case of models with pharmaceutical effects we 
added the chemical into perfused ACSF with the syringe. We used the concentrations 
resulting from the empirical and mentioned in reviews of previous researches. 
 All these changes were written down into the protocol and the spontaneous 
activity was expected. 
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4.4  DATA RECORDINGS AND ANALYSIS 
 
 Data recordings were made on PC in the program Spike 2 suitable for 
interpretation of the length of data, duration of evoked activity, amplitude, frequency 
and characteristics of evoked discharges. Data were stored on computer hard disc and 
analyzed off-line. 
 For detailed data evaluation we used the characterization of paired-pulse 
stimulation and its response (latency, amplitude, paired pulse index and Coast Line 
Index – CLI) in every experimental model of our research. Recording data were 
transferred into Microsoft Excel program and then analyzed.    
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5.  RESULTS 
 
 We evaluated eight hippocampal slices with the following results. We haven’t 
been able to elicit tonic clonic seizures in our setup that is the reason why we have 
devoted all our time to electrophysiological recordings. The only model whose activity 
resembled to seizure activity was the high-K+ model (Fig. 5.15 and 5.16). 
 With low-Mg2+ (Fig. 5.17), high-K+ 10mM (Fig. 5.15 and 5.16), Bicuculline in 
combination with high K+ (7mM KCl) (Fig. 5.18 and 5.19), 4-Aminopyridine (5.20) and 
except for Carbachol treated slices, we were able to elicit epileptic discharges. 
 We used paired pulse protocol with supramaximal intensity stimulation to assess 
changes in the activity of the slices and to evaluate the alteration in the excitability of 
the tissue (examples of this stimulation are imaged in Fig. 5.5 - 5.14).  
 As a comparison of these paired pulse stimulations we used a measurement of 
latency (in seconds) and amplitude (in milivolts). For this purpose we marked the line 
with following indicators (Fig. 5.1) of population spike - popspike (beginning of 
stimulation, early EPSP - excitatory postsynaptic potential, postsynaptic spike, late 
EPSP) and then we calculated a paired pulse index (PPI): 
PPI = amplitude popspike2/amplitude popspike1 
 
The number of this index indicates a presence of potentiation (PPI > 1) or depression 
(PPI < 1) in evoked responses of each pulse in paired pulse stimulation. 
 Then we calculated Coast Line Index (CLI) for each pulse (CLI1 and CLI2) in 
paired pulse stimulation again.  
 
CLI = longitude of the recording line/0.01  
 
This index represents a response characterization on impulse, respectively how much 
the recording line oscillates in time (in this case in 1ms), measured from the 
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postsynaptic spike indicator (see Fig. 5.1). Then we can imagine the excitability of 
stimulated tissue, the higher number the more excitable tissue (for results see Fig. 5.2 
and 5.3).  
 Finally, we compared four slices in one day (2. 4. 2010) made in 4-AP model. It 
compares CLI index, respectively CLI2 in regular ACSF at the beginning of recordings 
and CLI2 in 250μM 4-AP model. We evaluated the results in percentage (how does this 
value increase or increase compared to CLI1 (see Fig. 5.4).     
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Figure 5.1: Indicators of evoked response (from left, 1 - stimulation, 2 - early EPSP, 3 - 
postsynaptic spike, 4 - late EPSP) 
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Figure 5.2: Data collection (1pop = latency of population spike in 1st pulse; 2pop = 
latency of population spike in 2nd pulse)   
 
 
Date/slice/time (s) Model 1pop (s) 1popspike (mV) 2pop (s) 
2popspike 
(mV) 
020410/c/134 ACSF 0.00547 0.462112425 0.00578 0.7345963
020410/c/3200 250uM 4-AP 0.0051 3.208618199 0.0048 3.638916
020410/c/4520 ACSF wash 0.0044 2.135162365 0.0047 1.4019394
020410/c/4513 ACSF wash 0.0045 1.370353705 0.004325 1.4542389
020410/b/573 ACSF 0.0045 0.463447575 0.00415 0.6104279
020410/b/1621 250uM 4-AP 0.0053 1.259460465 0.0049 0.7180023
020410/a/241 ACSF 0.00945 0.396690369 0.00947 0.4853439
020410/a/3791 250uM 4-AP 0.0046 1.116447466 0.0045 1.0322571
020410/d/46 ACSF 0.004775 0.29312134 0.004625 0.3103638
020410/d/2267 250uM 4-AP 0.005 0.918998705 0.0046 0.6985856
150210/a/830 low Mg 0.00778 0.2525711 0.01065 0.3694916
150210/a/1410 ACSF 0.0031 0.293083155 0.0058 0.3701401
150210/a/1666 13uM Bicuculline 0.0031 0.341377265 0.003 0.2521133
150210/a/3115 33uM Bicuculline 0.0033 0.32867432 0.0031 0.2455139
150210/c/710 ACSF 0.0065 0.288391109 0.00635 0.365448
150210/c/1307 30uM Bicuculline 0.0069 0.554161075 0.0075 0.6229019
150210/c/1930 30uM Bic + 200uM Carbachol 0.001 0.909156815 0.0006 0.0971603
150210/c/2064 low Mg 0.0034 0.26443479 0.0034 0.3070831
150210/c/4678 wash ACSF 0.0008 0.6487656 0.0009 0.6465149
150210/b/355 ACSF 0.0047 0.791091917 0.00438 0.8278275
150210/b/1303 50uM Bicuculline 0.004 1.13296509 0.0038 1.3227463
150210/b/2553 low Mg 0.0027 1.38557432 0.0031 1.0235214
150210/b/3455 ACSF wash 0.0036 1.31244659 0.0035 1.4216614
231009/a/52 ACSF 0.0045 1.370353705 0.004325 1.4542389
231009/a/695 10mM KCl 0.00363 0.0725937 0.00725 0.0540542
231009/a/4711 ACSF wash 0.0044 0.90351105 0.0044 0.9984971
 
Note: 1-2pop = latency of population spike in 1st – 2nd pulse; 1-2popspike = amplitude in 1st – 2nd pulse   
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Figure 5.3: Data evaluation (paired pulse index, Coast Line index) 
 
 
Date/slice/time (s) Model Paired pulse index CLI1 CLI2 
020410/c/134 ACSF 1.589648352 163.8105 234.5124
020410/c/3200 250uM 4-AP 1.13410688 864.5574 971.3748
020410/c/4520 ACSF wash 0.65659616 472.2708 553.7368
020410/c/4513 ACSF wash 1.061214272 515.2155 621.4124
020410/b/573 ACSF 1.317145429 212.4151 255.7017
020410/b/1621 250uM 4-AP 0.570087212 558.9084 358.7042
020410/a/241 ACSF 1.223483023 124.975 143.088
020410/a/3791 250uM 4-AP 0.924590841 491.0737 430.4463
020410/d/46 ACSF 1.058823506 159.0301 164.4512
020410/d/2267 250uM 4-AP 0.760159455 280.4199 252.2142
150210/a/830 low Mg 1.462921134 648.915 200.3217
150210/a/1410 ACSF 1.262918266 355.2399 192.1733
150210/a/1666 13uM Bicuculline 0.738518264 189.1159 367.1251
150210/a/3115 33uM Bicuculline 0.746982347 232.4215 299.7635
150210/c/710 ACSF 1.267195777 196.3368 322.1121
150210/c/1307 30uM Bicuculline 1.124044864 316.6129 642.2662
150210/c/1930 30uM Bic + 200uM Carbachol 0.106868621 293.8525 437.2391
150210/c/2064 low Mg 1.16128101 327.3163 681.7322
150210/c/4678.08 wash ACSF 0.996530796 648.43 530.8557
150210/b/355 ACSF 1.046436498 339.1489 624.5852
150210/b/1303 50uM Bicuculline 1.167508436 633.2958 255.7017
150210/b/2553 low Mg 0.738698325 654.2572 358.7042
150210/b/3455 ACSF wash 1.083214662 610.6081 143.088
231009/a/52 ACSF 1.061214272 515.2155 621.4124
231009/a/695 10mM KCl 0.744613513 362.7661 624.0694
231009/a/4711 ACSF wash 1.105129871 850.6203 887.6747
 
Note: CLI1 = 1st pulse; CLI2=2nd pulse) 
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Figure 5.4: Comparison of CLI1 a CLI2 in regular ACSF a 4-AP model in all 
experimental slice in 2. 4. 2010 (increase or decrease of CLI2 in the 2nd pulse in 
percentage) 100% was set as the popspike of the first response 
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Note 1: 1 - experiment 020410/slice c/, 2 - experiment 020410/slice b, 3 - experiment 020410/slice a, 4 - 020410/slice d 
 
Note 2: In the first slice, we were able to evoke epileptic discharges, in the followings not, as we can see the values of 
the second stimulus response increased (potentiation) in the first slice and decrease in the other treated slices, which 
will be further discussed. 
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PAIRED PULSE STIMULATION 
 
 
 Following list includes the imagings of paired pulse stimulation and its 
responses. For imagination, it shows one example of every type in concentration of 
ACSF in certain recording situation  (regular ACSF,  ACSF wash - after using a 
pretreatment, low Mg2+, high K+, Bicuculline, Carbachol , 4-AP). 
 
 
Figure 5.5: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: Regular ACSF , 15. 2. 2010, slice b, 355s 
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Figure 5.6: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: ACSF wash , 23. 10. 2009, slice a, 4711s 
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Figure 5.7: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: Low Mg2+, 15. 2. 2010, slice a, 830s 
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Figure 5.8: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: 4-AP , 2. 4. 2010, slice c, 3200s 
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Figure 5.9: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: High K+ (10mM KCl), 23. 10. 2009, slice a, 695 s 
 
 
Keyboard31
3.5
3.4
3.3
3.2
3.1
3.0
2.9
2.8
2.7
2.6
2.5
2.4
2.3
2.2
m
V
di
ff
.
1
694.86 694.87 694.88 694.89 694.90 694.91 694.92 694.93 694.94 694.95 694.96 694.97 694.98 694.99 695.00 695.01 695.02 695.03 695.04 695.05
s  
 
 
 
Figure 5.10: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: 30μM Bicuculline + 200μM Carbachol, 15. 2. 2010, slice c, 
1930s 
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Figure 5.11: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: 13μM Bicuculline, 15. 2. 2010, slice a, 1666s 
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Figure 5.12: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: 33μM Bicuculline, 15. 2., slice a, 3115s 
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Figure 5.13: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: 30μM Bicuculline, 15. 2., slice c, 1307s 
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Figure 5.14: Example of paired pulse stimulation response, supramaximal stimulation 
intensity, conditions: 50μM Bicuculline, 15. 2., slice b, 1303s 
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EPILEPTIC DISCHARGES 
 
 Following list includes the examples of discharges which were successfully 
evoked in four experimental models as we mentioned in results.  
 
 
Figure 5.15: High K+ (10mM KCl) - seizure like activity 23. 10. 2010, slice a 
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Figure 5.16: High K+ (10mM KCl) - seizure like activity (zoom +) 23. 10. 2010, slice a 
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Figure 5.17: Low-Mg2+ (zero Mg2+), 15. 2. 2010, slice a 
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Figure 5.18: Bicuculline 13μM in combination with high K+ 7mM and after 
pretreatment with zero Mg2+, 15. 2. 2010, slice a 
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Figure 5.19: Bicuculline 13μM in combination with high K+ 7mM and after 
pretreatment with zero Mg2+ (zoom +), 15. 2. 2010, slice a  
 
 
Key board31
0.825
0.800
0.775
0.750
0.725
0.700
0.675
0.650
0.625
0.600
0.575
0.550
0.525
0.500
0.475
0.450
0.425
0.400
0.375
0.350
0.325
0.300
0.275
m
V
di
ff.1
2870.10 2870.15 2870.20 2870.25 2870.30 2870.35 2870.40 2870.45 2870.50
s  
 
 
 
Figure 5.20: 4-AP (250μM), 2. 4. 2010, slice c 
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6.  DISSCUSION 
 
 
6.1  DISSCUSION - METHODS 
 
 We used a submerged type of chamber for maintenance of rat hippocampal 
slices and for recordings of electric activity in this tissue. 
 When using a submerged chamber, it brings some advantages for experiment 
because specifications used for slice maintenance remind more in vivo conditions; there 
is no gaseous atmosphere too and the cells are in direct contact and surrounded by 
liquid. And even more, this chamber is necessary for ability to perform the imaging 
techniques. 
   But simulation of in vitro conditions in this chamber brings many difficulties 
too because the cells definitely need a sufficient amount of oxygen supply and other 
substances for their nutrition such as glucose and it has to maintained in the constant 
ionic environment so that is the reason why ACSF must flow in adequate speed 
(5ml/min in our setup). This fast overflow of solution may cause a movement of the 
slice in the chamber and these movements and the noise resulting from a permanent 
flow of ACSF could disturb the detection of signal and transfer these noises into the 
recording data and it could be even harmful for the slice. 
 Unfortunately, this type of maintenance and recording of tissue still interferes 
with some crucial differences compared to real organism such a slower washout of the 
ions from the extracellular space and the difference in oxygen availability that could 
cause apparent discrepancies in the assessment of cell’s function and its reaction to the 
stimulation. Oxygen is further delivered only through the diffusion in this non-vascular 
tissue and does not react on the energy demand via increase in blood flow which would 
normally occur in vivo after increased tissue demands. 
 Another important issue of experiment is the temperature at which is the tissue 
maintained because membrane receptors open and get activated only in certain 
temperature and SLE is very difficult to induce at temperatures below 33°C. The higher 
 81
temperature facilitated opening of for example NMDA receptors and the excitability is 
increased and it is well know that during febrile states especially in children, it can lead 
to so called febrile seizures (Hopkins et al., 1995). 
 Finally, it is necessary to pay high attention to preparation and cutting 
experimental tissue. This process must be done as quickly as possible, with sufficient 
oxygen supply and kept in stable temperature to maintain the viability of the slice and 
accomplished preciously to preserve maximal amount of intact neuronal connections. 
Even a little discrepancy in the angle of cutting and preparation can damage many 
connections and destroy the tissue. These conditions are therefore imperative for 
following manipulation within slices and correct recordings without any 
misunderstandings.    
 
6.2  DISSCUSION - RESULTS 
 
         In vitro studies made on rat brain slices and slice cultures are suitable for the 
stimulation of electrical activity which is similar to seizure activity we detect in vivo in 
certain pathophysiological states. Our aim in this study was to set several models of 
epileptic tonic-clonic activity in vitro that would be suitable for the detection of NO 
production in condition during states of abnormal seizure activity. 
 In our conditions we were so far not able to find a good model for such 
detection. We have picked up several models that disrupt normal activity by increasing 
the excitability and can lead and often lead to epileptic discharges. 
 The most reliable models of seizure activity in vitro were set especially while 
working on tissue cultures. Our situation is little bit more difficult because of the fact 
we are working with acute slices of the hippocampus where the neurons are damaged 
during cutting of the tissue and eliciting seizure activity is therefore harder considering 
damaged cells and worse connectivity.  
 Finally we were not able to elicit seizure like event with tonic-clonic seizures in 
any model that was available. That is the reason why we used for the discussion of the 
results the evaluation of paired pulse stimulation protocol to at least access the changes 
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in the excitability. Further we evaluated the Coast Line Index to have the other criteria 
mainly for the cases where the shape of the evoked response changed and where the 
length of the whole curve was longer. 
 The only model whose activity resembled to seizure activity was the high 
potassium model (Fig 5.15 and 5.16), where we were able to elicit discharges with the 
concentration of 10mM and depolarization of the tissue which might be hold as a 
seizure. The increased potassium level occurs at seizure activity (around 8mM 
(Leschinger et al., 1993) and increases the excitability of neurons. We were still not 
entirely satisfied with this model because neither we could elevate the level of 
potassium concentration or sustain this lever for longer time because 10mM 
concentration was rather high and such elevated level of potassium could possibly lead 
to status called spreading depression, which is long lasting wave of depolarization of the 
tissue and this would prevent the tissue from activity. The suitable model would be to 
start this activity with 10mM K+ and continued with 7 - 8mM but with such 
concentration we were not able to sustain the activity. Paired pulse measurement 
indicates the depression in response and CLI higher excitability of the tissue.   
 For the other model we tried Bicuculline which acts through GABAA receptors 
and inhibits the GABA inhibition of interneurons and therefore increases the 
excitability. With our model, we were not that successful in eliciting neither the seizures 
nor epileptic discharges. The only slice where we were able to get epileptic discharges 
(13 and 33μM) we would be able to describe as a bursting activity (Fig. 5.18 and 5.19) 
were the slices pretreated with zero Mg2+ model (tonic activation of NMDA receptors). 
We conclude that the tonic activation of the slice is able to change the properties of the 
nervous tissue and start epileptogenesis and might be of our further interest while 
searching for the other new model. Evaluation of paired pulse response (Fig. 5.11 for 
13μM Bicuculline, Fig. 5.12 for 33μM Bicuculline, Fig. 5.13 for 30μM Bicuculline and 
Fig. 5.14 for 50μM Bicuculline) and CLI displays higher excitability in the tissue, 
except of model with 50μM Bicuculline where the tissue seemed to be over stimulated 
because of high concentration of Bicuculline.  
 4AP was used in the concentration of 250μM according to previous protocol 
(Schuchmann et al., 1999). With this model, we were not able to elicit seizure like 
activity. In one slice of four (Fig. 5.20) there was interictal activity which would not be 
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probably sufficient activity for the detection of the NO production. The evaluation of 
paired pulse stimulation and Coast Line Indexes showed increased excitability in terms 
of regular ACSF concentration but not in 4-AP model; and paired pulse index evaluates 
the potentiation in ACSF in every slice and depression in 3 of 4 slices treated with 4-AP 
(Fig. 5.3). Comparison of CLI1 and CLI2 both terms (ACSF and 4-AP) in graph in 
percentage evaluate that there is an increase of excitability in ACSF but decrease in 4-
AP (Fig. 5.4). 
 The other idea was to use Carbachol in the concentration of 200μM to influence 
cholinergic pathways in combination of 33μM Bicuculline to start the seizure (Fig. 
5.10). But the effect was opposite and we inhibited the activity, which lead to the 
decrease of the pair pulse response and decrease in the latency of the second response 
(Fig. 5.2 and 5.3).    
 The final model I am going to mentioned is zero Mg2+. Firstly we wanted to 
avoid the model of zero Mg2+ because of the massive tonic activation of NMDA 
receptors that is not natural and wouldn’t be possible to be simulated in vivo. We 
evoked epileptic discharges in this model (Fig. 5.17). Unfortunately even with this 
model, we were not able to elicit tonic-clonic seizures, which might lead to assumption 
that in our conditions we are not able to elicit this kind of activity at all and so we 
should think about some changes in our experimental conditions such as ACSF flow, 
temperature, position of slice in the chamber or cutting slices. 
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7.  CONCLUSIONS 
 
 
 We were not able to elicit tonic-clonic seizures that we would need for further 
detection of NO production. The only model whose activity resembled to seizure 
activity was the high-K+ model (10mM). 
 We were able to elicit epileptic discharges during low-Mg2+ (zero Mg2+), the 
model evoking the massive tonic activation of NMDA receptors; high-K+ (10mM), the 
only model whose activity resembled to seizure activity; Bicuculline (13μM and 33μM) 
in combination with high K+ (7mM KCl) and pretreatment with zero Mg2+, the model 
based on inhibition of GABA which results in epileptic discharges only in one slice and 
with the characteristics of bursting activity; and 4-Aminopyridine (250μM), the model 
in which we evoked interictal activity but probably not sufficient for the detection of the 
NO production. 
 We suggest that we will have to change the measuring conditions of the tissue 
for further success in eliciting the epileptiform activity in rat hippocampal slice in vitro   
regarding different ACSF flow or temperature or position of the tissue in the chamber or 
to play around with the cutting of the hippocampal slices to improve the conditions for 
slice. 
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8.  ABBREVIATIONS 
 
 
ACSF - artificial cerebrospinal fluid 
AMPA - amino-3-hydroxy-5-methylisoxazolepropionic acid 
ADP – adenosine diphosphate 
ATP - adenosine triphosphate 
BOLD fMRI - functional magnetic resonance imaging 
Ca - Calcium 
cGMP - cyclic guanosine monophosphate 
CNS - central nervous system 
CSF - cerebrospinal fluid 
DG - dentate gyrus 
EC - entorhinal cortex 
EEG - electroencephalography 
GABA - γ-aminobutyric acid 
K - Potassium 
KA - kainic acid 
L-NAME - N (G)-nitro-L- arginine methyl ester (hydrochloride) 
L-PIA - L-phenyl isopropyl adenosine 
LTD - long-term depression 
LTP - long-term potentiation 
Mg - magnesium 
MS - Multiple Sclerosis 
NADH - nicotinamide adenine dinucleotide 
NADPH - α-nicotinamide adenine dinucleotide phosphate 
NMDA - N-methyl-D-aspartate 
NO - nitric oxide 
NOS - nitric oxide synthase 
eNOS - endothelial nitric oxide synthase 
iNOS - inducible nitric oxide synthase 
nNOS - neuronal nitric oxide synthase 
PDS - paroxysmal depolarization shift 
 86
PTE - posttraumatic epilepsy 
ROI - region of interest 
SD - spreading depression 
SLE - seizure-like event 
T - threshold 
4-AP - 4-Aminopyridine 
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